PKC INHIBITOR SOLID STATE FORMS

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims benefit of U.S. Patent Application No. 62/511,210, filed on May 25, 2017, which is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

[0002] The present disclosure relates to a protein kinase inhibitor compound and pharmaceutical compositions of said compound as well as the use of said compound in pharmaceutical

compositions and medicine.

SUMMARY OF THE INVENTION

[0003] The present disclosure relates to various solid state forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine and methods of making the same. Such forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine are useful in the treatment of cancer, immune disorders and inflammation.

[0004] Provided herein is a composition comprising amorphous 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine .

[0005] Provided herein is a composition comprising crystalline 2-propanol solvate Form A of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro-

2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropy rrolo[3,4-c]pyrazol-3-amine.

[0006] Provided herein is a composition comprising crystalline 2-propanol solvate Form A of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro-

2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropy rrolo[3,4-c]pyrazol-3-amine is characterized by an X-ray diffraction pattern reflection at a 2 theta value of 18.1.

[0007] Provided herein is a composition comprising crystalline hydrate Form B of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine.

[0008] Provided herein is a composition comprising crystalline hydrate Form B of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6 etrahydropyrrolo[3,4-c]pyrazol-3-amine characterized by an X-ray diffraction pattern reflection at a 2 theta value of 16.3.

[0009] Provided herein is a composition comprising crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine.

[0010] Provided herein is a composition comprising crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine characterized by an X-ray diffraction pattern reflection at a 2 theta value of 17.9.

[0011] Provided herein is a composition comprising crystalline hydrate Form L of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine.

[0012] Provided herein is a composition comprising crystalline hydrate Form L of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine characterized by an X-ray diffraction pattern reflection at a 2 theta value of 17.3.

[0013] Provided herein is a composition comprising crystalline Form G of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine.

[0014] Provided herein is a composition comprising crystalline hydrate Form G of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine characterized by an X-ray diffraction pattern reflection at a 2 theta value of 4.4.

[0015] Provided herein is a composition comprising crystalline Form H of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine.

[0016] Provided herein is a composition comprising crystalline hydrate Form H of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine characterized by an X-ray diffraction pattern reflection at a 2 theta value of 4.4.

[0017] Provided herein is a composition comprising crystalline Form I of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine. [0018] Provided herein is a composition comprising crystalline hydrate Form I of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine characterized by an X-ray diffraction pattern reflection at a 2 theta value of 15.7.

[0019] Provided herein is the compound 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone.

[0020] Provided herein is the compound 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, substantially free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone.

[0021] Provided herein is the compound 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate.

[0022] Provided herein is the compound 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine, or a pharmaceutically acceptable salt, solution or hydrate thereof, substantially free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate.

[0023] Provided herein is a pharmaceutical composition comprising amorphous 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine and at least one pharmaceutically acceptable excipient. [0024] Provided herein is a pharmaceutical composition comprising crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine and at least one pharmaceutically acceptable excipient.

[0025] Provided herein is a pharmaceutical composition comprising crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine and at least one pharmaceutically acceptable excipient.

[0026] Provided herein is a pharmaceutical composition comprising crystalline hydrate Form L of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine and at least one pharmaceutically acceptable excipient.

[0027] Provided herein is a pharmaceutical composition comprising crystalline Form G of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine and at least one pharmaceutically acceptable excipient.

[0028] Provided herein is a pharmaceutical composition comprising crystalline Form H of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine and at least one pharmaceutically acceptable excipient.

[0029] Provided herein is a pharmaceutical composition comprising crystalline Form I of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine and at least one pharmaceutically acceptable excipient.

[0030] Provided herein is a pharmaceutical composition comprising 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine and at least one pharmaceutically acceptable excipient.

INCORPORATION BY REFERENCE

[0031] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] The features of the invention are set forth with particularity in the appended claims. A better understanding of the features of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

Figure 1 shows the X-ray powder diffractogram of amorphous solid 5-{[(2S,5R)-2,5-dimethyl- 4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N -(5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine ;

Figure 2a shows the differential scanning calorimetry pattern of amorphous solid 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine;

Figure 2b shows the thermal gravimetric analysis pattern of amorphous solid 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine;

Figure 3 shows the X-ray powder diffractogram of crystalline 2-propanol solvate Form A of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine;

Figure 4 shows the X-ray powder diffractogram of crystalline 2-propanol solvate Form A of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine without annotation;

Figure 5 shows the differential scanning calorimetry thermogram of crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine;

Figure 6 shows the thermal gravimetric analysis thermogram of crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine;

Figure 7 shows the infrared spectrum of crystalline 2-propanol solvate Form A of 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine without annotation; Figure 8 shows the infrared spectrum of crystalline 2-propanol solvate Form A of 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine] with peaks numerically identified at all wavenumbers;

Figure 9 shows the infrared spectrum of crystalline 2-propanol solvate Form A of 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine with peaks numerically identified at low wavenumbers;

Figure 10 shows the X-ray powder diffractogram of crystalline hydrate Form B of 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine with peaks numerically identified;

Figure 11 shows the X-ray powder diffractogram of crystalline hydrate Form B of 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine without annotation;

Figure 12 shows the differential scanning calorimetry thermogram of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine;

Figure 13 shows the thermal gravimetric analysis thermogram of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine;

Figure 14 shows the infrared spectrum of crystalline hydrate Form B of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine;

Figure 15 shows the Raman spectrum of crystalline hydrate Form B of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine without annotation;

Figure 16 shows the Raman spectrum of crystalline hydrate Form B of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine with peaks numerically identified; Figure 17 shows the X-ray powder diffractogram of crystalline hydrate Form D of 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine with peaks numerically identified;

Figure 18 shows the X-ray powder diffractogram of crystalline hydrate Form D of 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine without annotation;

Figure 19 shows the differential scanning calorimetry thermogram of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine;

Figure 20 shows the thermal gravimetric analysis thermogram of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine;

Figure 21 shows the infrared spectrum of crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine];

Figure 22 shows the Raman spectrum of crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine without annotation;

Figure 23 shows the Raman spectrum of crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine with peaks numerically identified;

Figure 24 shows the X-ray powder diffractogram of crystalline hydrate Form L of 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine with peaks numerically identified;

Figure 25 shows the X-ray powder diffractogram of crystalline hydrate Form L of 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine without annotation; Figure 26 shows the differential scanning calorimetry thermogram of crystalline hydrate Form L of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine;

Figure 27 shows the thermal gravimetric analysis thermogram of crystalline hydrate Form L of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine;

Figure 28 shows the infrared spectrum of crystalline hydrate Form L of 5-{ [(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine;

Figure 29 shows the Raman spectrum of crystalline hydrate Form L of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine without annotation;

Figure 30 shows the Raman spectrum of crystalline hydrate Form L of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine with peaks numerically identified;

Figure 31 shows the X-ray powder diffractogram of crystalline Form G of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine with peaks numerically identified;

Figure 32 shows the X-ray powder diffractogram of crystalline Form G of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine without annotation;

Figure 33 shows the differential scanning calorimetry thermogram of crystalline Form G of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine;

Figure 34 shows the thermal gravimetric analysis thermogram of crystalline Form G of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine;

Figure 35 shows the X-ray powder diffractogram of crystalline Form H of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine with peaks numerically identified;

Figure 36 shows the X-ray powder diffractogram of crystalline Form H of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine without annotation;

Figure 37 shows the differential scanning calorimetry thermogram of crystalline Form H of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine;

Figure 38 shows the thermal gravimetric analysis thermogram of crystalline Form H of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine;

Figure 39 shows the X-ray powder diffractogram of crystalline Form I of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine with peaks numerically identified;

Figure 40 shows the X-ray powder diffractogram of crystalline Form I of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine without annotation;

Figure 41 shows the differential scanning calorimetry thermogram of crystalline Form I of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine;

Figure 42 shows the thermal gravimetric analysis thermogram of crystalline Form I of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine;

Figure 43 shows the X-ray powder diffractogram of the "input solid" for the isolation experiments in Example 18, which is the amorphous solid of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine ;

Figure 44 shows the X-ray powder diffractogram of the solid isolated from CH ₃ CN post chromatography in Example 18 A;

Figure 45 shows the X-ray powder diffractogram comparison of the input solid (top) and of the damp solid (bottom) of the solid isolated from 9: 1 CH ₃ CN/water post chromatography and evaporation at 18 °C overnight in Example 18B, demonstrating a partially crystalline pattern of the isolated solid;

Figure 46 shows the X-ray powder diffractogram comparison of the input solid (top) and of the dry solid (bottom) of the solid isolated from 9: 1 CH ₃ CN/water post chromatography and evaporation at 18 °C overnight, and then further evaporation at 35 °C in Example 18B,

demonstrating a partially crystalline pattern of the isolated solid;

Figure 47 shows the X-ray powder diffractogram comparison of the input solid (top) and of the damp solid (bottom) of the solid isolated from 1 :9 CH ₃ CN/water post chromatography and evaporation at 18 °C overnight in Example 18C, demonstrating a highly crystalline pattern of the isolated solid;

Figure 48 shows the X-ray powder diffractogram comparison of the input solid (top) and of the dry solid (bottom) of the solid isolated from 1 :9 CH ₃ CN/water post chromatography and evaporation at 18 °C overnight, and then further evaporation at 35 °C in Example 18C,

demonstrating a highly crystalline pattern of the isolated solid; and

Figure 49 shows an expansion of the X-ray powder diffractogram comparison of the damp solid isolated from Example 18B (top), of the damp solid isolated from Example 18C (middle), and of crystalline hydrate Form L of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine (bottom), demonstrating that the solid forms isolated in Examples 18B and 18C correspond to crystalline hydrate Form L.

DETAILED DESCRIPTION OF THE INVENTION

[0033] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

[0034] Compounds that are kinase inhibitors have the potential to provide therapeutically effective pharmaceutical compositions that would be expected to have beneficial and improved

pharmaceutical properties for the treatment of kinase related conditions or disorders such as cancer and other proliferative disorders.

[0035] Discussed herein is 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine and referred to herein as Compound 1. Compound 1 has been previously described in WO 2008/096260 and related patents and patent applications, e.g. US 8, 183,255, US 8,877,761, US 9,518,060 and US patent application 15/376,279, each of which is incorporated by reference in their entiret .

Compound 1

5- { [(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmemyl)piperazin- 1 -yl]carbonyl} - N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6- dimethyl-l,4,5,6-tetrahydropyrrolo[3,4- c]pyrazol-3 -amine

[0036] A summary of the Protein Kinase C (PKC) inhibition by Compound 1 is provided in Table 1. The methods for these determinations have been described (Grant, et al. 2010, Eur. J. Pharmacol. 627: 16-25). Compound 1 is a potent, ATP-competitive and reversible inhibitor of conventional PKC enzymes with a Ki = 5.3 nM for recombinant PKC beta and a Ki = 10.4 nM for recombinant PKC alpha. It also is a potent inhibitor of the novel isoform PKC theta with an IC ₅₀ = 25.6 nM. Furthermore, it demonstrated some potency for conventional isoform PKC gamma with an IC ₅₀ = 57.5 nM. Otherwise, it demonstrated a high degree of selectivity for the other members of the conventional, novel and atypical isoforms of PKC as shown by lower potency against these isoforms (Table 1). Compound 1 does not significantly inhibit PKC delta.

Table 1

In Vitro Assays IC ₅₀ (nM) Ki (nM)

Human PKC alpha 10.4

Human PKC betall 5.3

Human PKC alpha 2.3

Human PKC betal 8.1

Human PKC betall 7.6

Human PKC theta 25.6

Human PKC gamma 57.5

Human PKC mu 314

Human PKC epsilon 808

Human PKC delta > 1000

Human PKC eta > 1000 Human PKC iota > 1000

Human PKC zeta > 1000

Human PRKCN (PKD3) 131

pSHP2 (PKCP cell assay) 9.8

Interleukin-8 release 39

[0037] As a selective inhibitor of PKC, Compound 1 is useful in the treatment of conditions in which PKC has demonstrated a role in the pathology, such as cancer, immune disorders and inflammation. Two critical aspects in the development of Compound 1 as a useful therapy for such diseases and disorders are the discovery of practical methods for the preparation of Compound 1, and the discovery of pharmaceutically acceptable forms of Compound 1 and pharmaceutical compositions comprising said forms.

[0038] As used herein, the term "amorphous" or "amorphous solid form" refers to a solid form which is substantially free of any crystalline solid state form. One embodiment provides a composition wherein substantially free means less than about 10 % (w/w), less than about 9 % (w/w), less than about 8 % (w/w), less than about 7 % (w/w), less than about 6 % (w/w), less than about 5 % (w/w), less than about 4.75 % (w/w), less than about 4.5 % (w/w), less than about 4.25 % (w/w), less than about 4 % (w/w), less than about 3.75 % (w/w), less than about 3.5 % (w/w), less than about 3.25 % (w/w), less than about 3 % (w/w), less than about 2.75 % (w/w), less than about 2.5 % (w/w), less than about 2.25 % (w/w), less than about 2 % (w/w), less than about 1.75 % (w/w), less than about 1.5 % (w/w), less than about 1.25 % (w/w), less than about 1 % (w/w), less than about 0.9 % (w/w), less than about 0.8 % (w/w), less than about 0.7 % (w/w), less than about 0.6 % (w/w), less than about 0.5 % (w/w), less than about 0.4 % (w/w), less than about 0.3 % (w/w), less than about 0.25 % (w/w), less than about 0.20 % (w/w), less than about 0.15 % (w/w), less than about 0.1 % (w/w), less than about 0.08 % (w/w), or less than about 0.05 % (w/w). One embodiment provides a composition wherein substantially free means an undetectable amount. One embodiment provides a composition wherein substantially free means less than about 5 % (w/w), less than about 3 % (w/w), less than about 1 % (w/w), less than about 0.5 % (w/w), or less than about 0.2 % (w/w).

[0039] As used herein, the term "crystalline," "highly crystalline," "crystalline solid form," or "highly crystalline solid form" refers to a solid form which is substantially free of any amorphous solid state form. In some embodiments, the crystalline solid form is a single solid state form, e.g. crystalline Form A. One embodiment provides a composition wherein substantially free means less than about 10 % (w/w), less than about 9 % (w/w), less than about 8 % (w/w), less than about 7 % (w/w), less than about 6 % (w/w), less than about 5 % (w/w), less than about 4.75 % (w/w), less than about 4.5 % (w/w), less than about 4.25 % (w/w), less than about 4 % (w/w), less than about 3.75 % (w/w), less than about 3.5 % (w/w), less than about 3.25 % (w/w), less than about 3 % (w/w), less than about 2.75 % (w/w), less than about 2.5 % (w/w), less than about 2.25 % (w/w), less than about 2 % (w/w), less than about 1.75 % (w/w), less than about 1.5 % (w/w), less than about 1.25 % (w/w), less than about 1 % (w/w), less than about 0.9 % (w/w), less than about 0.8 % (w/w), less than about 0.7 % (w/w), less than about 0.6 % (w/w), less than about 0.5 % (w/w), less than about 0.4 % (w/w), less than about 0.3 % (w/w), less than about 0.25 % (w/w), less than about 0.20 % (w/w), less than about 0.15 % (w/w), less than about 0.1 % (w/w), less than about 0.08 % (w/w), or less than about 0.05 % (w/w). One embodiment provides a composition wherein substantially free means an undetectable amount. One embodiment provides a composition wherein substantially free means less than about 5 % (w/w), less than about 3 % (w/w), less than about 1 % (w/w), less than about 0.5 % (w/w), or less than about 0.2 % (w/w).

[0040] As used herein, the term "partially crystalline" or "partially crystalline material" refers to an ad-mixture of two or more solid state forms. In some embodiments, partially crystalline refers to an ad-mixture of an amorphous solid form and at least one crystalline solid form. Partially crystalline material is not amorphous.

[0041] In some embodiments, crystallinity of a solid form is determined by X-Ray Powder Diffraction (XRPD). In some embodiments, crystallinity of a solid form is determined by solid state MR.

[0042] Provided herein is the amorphous solid form of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine.

[0043] One embodiment provides a composition wherein the amorphous 5-{[(2S,5R)-2,5-dimethyl- 4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N -(5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine exhibits the X-ray powder diffraction pattern as shown in Figure 1.

[0044] One embodiment provides a composition wherein the amorphous 5-{[(2S,5R)-2,5-dimethyl- 4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N -(5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine exhibits a differential scanning calorimetry pattern shown in Figure 2a.

[0045] One embodiment provides a composition wherein the amorphous 5-{[(2S,5R)-2,5-dimethyl- 4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N -(5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine exhibits a thermogravimetric analysis pattern shown in Figure 2b. [0046] One embodiment provides a composition wherein the amorphous 5-{[(2S,5R)-2,5-dimethyl- 4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N -(5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is stable over 36 months at ambient temperature. One embodiment provides a composition wherein the amorphous 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is stable over 60 months at ambient temperature.

[0047] One embodiment provides a composition wherein the amorphous 5-{[(2S,5R)-2,5-dimethyl- 4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N -(5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine remains amorphous over 36 months at ambient temperature. One embodiment provides a composition wherein the amorphous 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine remains amorphous over 60 months at ambient temperature.

[0048] One embodiment provides a composition wherein the stability of amorphous 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is determined by the X-ray powder diffraction pattern.

[0049] Provided herein is the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-

4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl }-N-(5-fluoro-2-methylpyrimidin-4-yl)-

6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-am ine.

[0050] One embodiment provides a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine exhibits the X-ray powder diffraction pattern as shown in Figure 3.

[0051] Provided herein is a composition comprising crystalline 2-propanol solvate Form A of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is characterized by an X-ray diffraction pattern reflection at a 2 theta value of 18.1.

[0052] One embodiment provides a composition wherein the crystalline Form A is further characterized by X-ray diffraction pattern reflections at 2 theta values of 6.8, 15.3 and 22.1.

[0053] One embodiment provides a composition wherein the crystalline Form A is further characterized by X-ray diffraction pattern reflections at 2 theta values of 12.9, 13.6, 15.7, 17.2, 21.2, 21.7, 22.8 and 28.4. [0054] One embodiment provides a composition wherein the crystalline Form A is further characterized by at least one X-ray diffraction pattern reflection selected from a 2 theta value of

6.8, 12.9, 13.6, 15.3, 15.7, 17.2, 18.1, 21.2, 21.7, 22.1, 22.8 and 28.4.

[0055] One embodiment provides a composition wherein the crystalline Form A is further characterized by at least two X-ray diffraction pattern reflections selected from a 2 theta value of

6.8, 12.9, 13.6, 15.3, 15.7, 17.2, 18.1, 21.2, 21.7, 22.1, 22.8 and 28.4.

[0056] One embodiment provides a composition wherein the crystalline Form A is further characterized by at least three X-ray diffraction pattern reflections selected from a 2 theta value of

6.8, 12.9, 13.6, 15.3, 15.7, 17.2, 18.1, 21.2, 21.7, 22.1, 22.8 and 28.4.

[0057] One embodiment provides a composition wherein the crystalline Form A is further characterized by at least four X-ray diffraction pattern reflections selected from a 2 theta value of

6.8, 12.9, 13.6, 15.3, 15.7, 17.2, 18.1, 21.2, 21.7, 22.1, 22.8 and 28.4.

[0058] One embodiment provides a composition wherein the crystalline Form A is further characterized by at least five X-ray diffraction pattern reflections selected from a 2 theta value of

6.8, 12.9, 13.6, 15.3, 15.7, 17.2, 18.1, 21.2, 21.7, 22.1, 22.8 and 28.4.

[0059] One embodiment provides a composition wherein the crystalline Form A is further characterized by at least six X-ray diffraction pattern reflections selected from a 2 theta value of

6.8, 12.9, 13.6, 15.3, 15.7, 17.2, 18.1, 21.2, 21.7, 22.1, 22.8 and 28.4.

[0060] One embodiment provides a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine exhibits the differential scanning calorimetry pattern as shown in Figure 5.

[0061] One embodiment provides a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine exhibits the thermogravimetric analysis pattern as shown in Figure 6.

[0062] One embodiment provides a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine exhibits the infrared spectrum as shown in Figure 7, 8, or 9.

[0063] Provided herein is the crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-

(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-

6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-am ine. [0064] One embodiment provides a composition wherein the crystalline hydrate Form B of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the X-ray powder diffraction pattern as shown in Figure 10.

[0065] Provided herein is a composition comprising crystalline hydrate Form B of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine characterized by an X-ray diffraction pattern reflection at a 2 theta value of 16.3.

[0066] One embodiment provides a composition wherein the crystalline Form B is further characterized by X-ray diffraction pattern reflections at 2 theta values of 9.0, 10.9 and 15.0.

[0067] One embodiment provides a composition wherein the crystalline Form B is further characterized by X-ray diffraction pattern reflections at 2 theta values of 6.8, 9.2, 11.3, 14.8, 19.4, 20.0, 22.1, 23.0 and 26.8.

[0068] One embodiment provides a composition wherein the crystalline Form B is further characterized by at least one X-ray diffraction pattern reflection selected from a 2 theta value of

6.8, 9.0, 9.2, 10.9, 11.3, 14.8, 15.0, 16.3, 19.4, 20.0, 22.1, 23.0 and 26.8.

[0069] One embodiment provides a composition wherein the crystalline Form B is further characterized by at least two X-ray diffraction pattern reflections selected from a 2 theta value of

6.8, 9.0, 9.2, 10.9, 11.3, 14.8, 15.0, 16.3, 19.4, 20.0, 22.1, 23.0 and 26.8.

[0070] One embodiment provides a composition wherein the crystalline Form B is further characterized by at least three X-ray diffraction pattern reflections selected from a 2 theta value of

6.8, 9.0, 9.2, 10.9, 11.3, 14.8, 15.0, 16.3, 19.4, 20.0, 22.1, 23.0 and 26.8.

[0071] One embodiment provides a composition wherein the crystalline Form B is further characterized by at least four X-ray diffraction pattern reflections selected from a 2 theta value of

6.8, 9.0, 9.2, 10.9, 11.3, 14.8, 15.0, 16.3, 19.4, 20.0, 22.1, 23.0 and 26.8.

[0072] One embodiment provides a composition wherein the crystalline Form B is further characterized by at least five X-ray diffraction pattern reflections selected from a 2 theta value of

6.8, 9.0, 9.2, 10.9, 11.3, 14.8, 15.0, 16.3, 19.4, 20.0, 22.1, 23.0 and 26.8.

[0073] One embodiment provides a composition wherein the crystalline Form B is further characterized by at least six X-ray diffraction pattern reflections selected from a 2 theta value of

6.8, 9.0, 9.2, 10.9, 11.3, 14.8, 15.0, 16.3, 19.4, 20.0, 22.1, 23.0 and 26.8.

[0074] One embodiment provides a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6 etrahydropyrrolo[3,4-c]pyrazol-3-amine exhibits the differential scanning calorimetry pattern as shown in Figure 12.

[0075] One embodiment provides a composition wherein the crystalline hydrate Form B of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the thermogravimetric analysis pattern as shown in Figure 13.

[0076] One embodiment provides a composition wherein the crystalline hydrate Form B of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the infrared spectrum as shown in Figure 14.

[0077] Provided herein is the crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-

(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-

6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-am ine.

[0078] One embodiment provides a composition wherein the crystalline hydrate Form D of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the X-ray powder diffraction pattern as shown in Figure 17.

[0079] Provided herein is a composition comprising crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine characterized by an X-ray diffraction pattern reflection at a 2 theta value of 17.9.

[0080] One embodiment provides a composition wherein the crystalline Form D is further characterized by X-ray diffraction pattern reflections at 2 theta values of 8.3, 14.0 and 20.4.

[0081] One embodiment provides a composition wherein the crystalline Form D is further characterized by X-ray diffraction pattern reflections at 2 theta values of 5.5, 8.3, 10.5, 13.6, 16.7, 18.1, 18.7, 23.9, 24.8 and 28.2.

[0082] One embodiment provides a composition wherein the crystalline Form D is further characterized by at least one X-ray diffraction pattern reflection selected from a 2 theta value of 5.5, 8.3, 10.5, 13.6, 14.0, 16.7, 17.9, 18.1, 18.7, 20.4, 23.9, 24.8 and 28.2.

[0083] One embodiment provides a composition wherein the crystalline Form D is further characterized by at least two X-ray diffraction pattern reflections selected from a 2 theta value of 5.5, 8.3, 10.5, 13.6, 14.0, 16.7, 17.9, 18.1, 18.7, 20.4, 23.9, 24.8 and 28.2. [0084] One embodiment provides a composition wherein the crystalline Form D is further characterized by at least three X-ray diffraction pattern reflections selected from a 2 theta value of

5.5, 8.3, 10.5, 13.6, 14.0, 16.7, 17.9, 18.1, 18.7, 20.4, 23.9, 24.8 and 28.2.

[0085] One embodiment provides a composition wherein the crystalline Form D is further characterized by at least four X-ray diffraction pattern reflections selected from a 2 theta value of

5.5, 8.3, 10.5, 13.6, 14.0, 16.7, 17.9, 18.1, 18.7, 20.4, 23.9, 24.8 and 28.2.

[0086] One embodiment provides a composition wherein the crystalline Form D is further characterized by at least five X-ray diffraction pattern reflections selected from a 2 theta value of

5.5, 8.3, 10.5, 13.6, 14.0, 16.7, 17.9, 18.1, 18.7, 20.4, 23.9, 24.8 and 28.2.

[0087] One embodiment provides a composition wherein the crystalline Form D is further characterized by at least six X-ray diffraction pattern reflections selected from a 2 theta value of

5.5, 8.3, 10.5, 13.6, 14.0, 16.7, 17.9, 18.1, 18.7, 20.4, 23.9, 24.8 and 28.2.

[0088] One embodiment provides a composition wherein the crystalline hydrate Form D of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro-

2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropy rrolo[3,4-c]pyrazol-3-amine exhibits the differential scanning calorimetry pattern as shown in Figure 19.

[0089] One embodiment provides a composition wherein the crystalline hydrate Form D of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the thermogravimetric analysis pattern as shown in Figure 20.

[0090] One embodiment provides a composition wherein the crystalline hydrate Form D of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the infrared spectrum as shown in Figure 21.

[0091] Provided herein is the crystalline hydrate Form L of 5-{[(2S,5R)-2,5-dimethyl-4-

(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-

6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-am ine.

[0092] One embodiment provides a composition wherein the crystalline hydrate Form L of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the X-ray powder diffraction pattern as shown in Figure 24.

[0093] Provided herein is a composition comprising crystalline hydrate Form L of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine characterized by an X-ray diffraction pattern reflection at a 2 theta value of 17.3.

[0094] One embodiment provides a composition wherein the crystalline Form L is further characterized by X-ray diffraction pattern reflections at 2 theta values of 7.3, 7.7, 8.4, 11.2, 13.9, 17.8 and 23.4.

[0095] One embodiment provides a composition wherein the crystalline Form L is further characterized by X-ray diffraction pattern reflections at 2 theta values of 5.7, 8.7, 12.0, 14.3, 16.0, 16.5, 17.6, 17.8, 19.0, 20.3, 21.1 and 22.4.

[0096] One embodiment provides a composition wherein the crystalline Form L is further characterized by at least one X-ray diffraction pattern reflection selected from a 2 theta value of 5.7, 7.3, 7.7, 8.4, 8.7, 11.2, 12.0, 13.9, 14.3, 16.0, 16.5, 17.3, 17.6, 17.8, 19.0, 20.3, 21.1, 23.4 and 22.4.

[0097] One embodiment provides a composition wherein the crystalline Form L is further characterized by at least two X-ray diffraction pattern reflections selected from a 2 theta value of 5.7, 7.3, 7.7, 8.4, 8.7, 11.2, 12.0, 13.9, 14.3, 16.0, 16.5, 17.3, 17.6, 17.8, 19.0, 20.3, 21.1, 23.4 and 22.4.

[0098] One embodiment provides a composition wherein the crystalline Form L is further characterized by at least three X-ray diffraction pattern reflections selected from a 2 theta value of 5.7, 7.3, 7.7, 8.4, 8.7, 11.2, 12.0, 13.9, 14.3, 16.0, 16.5, 17.3, 17.6, 17.8, 19.0, 20.3, 21.1, 23.4 and 22.4.

[0099] One embodiment provides a composition wherein the crystalline Form L is further characterized by at least four X-ray diffraction pattern reflections selected from a 2 theta value of 5.7, 7.3, 7.7, 8.4, 8.7, 11.2, 12.0, 13.9, 14.3, 16.0, 16.5, 17.3, 17.6, 17.8, 19.0, 20.3, 21.1, 23.4 and 22.4.

[00100] One embodiment provides a composition wherein the crystalline Form L is further characterized by at least five X-ray diffraction pattern reflections selected from a 2 theta value of 5.7, 7.3, 7.7, 8.4, 8.7, 11.2, 12.0, 13.9, 14.3, 16.0, 16.5, 17.3, 17.6, 17.8, 19.0, 20.3, 21.1, 23.4 and 22.4.

[00101] One embodiment provides a composition wherein the crystalline Form L is further characterized by at least six X-ray diffraction pattern reflections selected from a 2 theta value of 5.7, 7.3, 7.7, 8.4, 8.7, 11.2, 12.0, 13.9, 14.3, 16.0, 16.5, 17.3, 17.6, 17.8, 19.0, 20.3, 21.1, 23.4 and 22.4.

[00102] One embodiment provides a composition wherein the crystalline hydrate Form L of

5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethy l)piperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6 etrahydropyrrolo[3,4-c]pyrazol-3-ami exhibits the differential scanning calorimetry pattern as shown in Figure 26.

[00103] One embodiment provides a composition wherein the crystalline hydrate Form L of

5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethy l)piperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine exhibits the thermogravimetric analysis pattern as shown in Figure 27.

[00104] One embodiment provides a composition wherein the crystalline hydrate Form L of

5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethy l)piperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine exhibits the infrared spectrum as shown in Figure 28.

[00105] Provided herein is the crystalline solid Form G of 5-{ [(2S,5R)-2,5-dimethyl-4-

(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-

6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-am ine.

[00106] One embodiment provides a composition wherein the crystalline Form G of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the X-ray powder diffraction pattern as shown in Figure 31.

[00107] Provided herein is a composition comprising crystalline hydrate Form G of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro-

2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropy rrolo[3,4-c]pyrazol-3-amine

characterized by an X-ray diffraction pattern reflection at a 2 theta value of 4.4.

[00108] One embodiment provides a composition wherein the crystalline Form G is further characterized by X-ray diffraction pattern reflections at 2 theta values of 6.4, 10.2, 12.8, 13.0, 14.0,

17.5, 17.8, 18.6, and 19.1.

[00109] One embodiment provides a composition wherein the crystalline Form G is further characterized by X-ray diffraction pattern reflections at 2 theta values of 6.2, 11.2, 14.5, 15.5, 16.0, 18.0, 20.6, 22.6, 22.9, and 28.4.

[00110] One embodiment provides a composition wherein the crystalline Form G is further characterized by at least one X-ray diffraction pattern reflection selected from a 2 theta value of 4.4, 6.2, 6.4, 10.2, 11.2, 12.8, 13.0, 14.0, 14.5, 15.5, 16.0, 17.5, 17.8, 18.0, 18.6, 19.1, 20.6, 22.6, 22.9, and 28.4.

[00111] One embodiment provides a composition wherein the crystalline Form G is further characterized by at least two X-ray diffraction pattern reflection selected from a 2 theta value of 4.4, 6.2, 6.4, 10.2, 11.2, 12.8, 13.0, 14.0, 14.5, 15.5, 16.0, 17.5, 17.8, 18.0, 18.6, 19.1, 20.6, 22.6, 22.9, and 28.4.

[00112] One embodiment provides a composition wherein the crystalline Form G is further characterized by at least three X-ray diffraction pattern reflection selected from a 2 theta value of 4.4, 6.2, 6.4, 10.2, 11.2, 12.8, 13.0, 14.0, 14.5, 15.5, 16.0, 17.5, 17.8, 18.0, 18.6, 19.1, 20.6, 22.6, 22.9, and 28.4.

[00113] One embodiment provides a composition wherein the crystalline Form G is further characterized by at least four X-ray diffraction pattern reflection selected from a 2 theta value of 4.4, 6.2, 6.4, 10.2, 11.2, 12.8, 13.0, 14.0, 14.5, 15.5, 16.0, 17.5, 17.8, 18.0, 18.6, 19.1, 20.6, 22.6, 22.9, and 28.4.

[00114] One embodiment provides a composition wherein the crystalline Form G is further characterized by at least five X-ray diffraction pattern reflection selected from a 2 theta value of 4.4, 6.2, 6.4, 10.2, 11.2, 12.8, 13.0, 14.0, 14.5, 15.5, 16.0, 17.5, 17.8, 18.0, 18.6, 19.1, 20.6, 22.6, 22.9, and 28.4.

[00115] One embodiment provides a composition wherein the crystalline Form G is further characterized by at least six X-ray diffraction pattern reflection selected from a 2 theta value of 4.4, 6.2, 6.4, 10.2, 11.2, 12.8, 13.0, 14.0, 14.5, 15.5, 16.0, 17.5, 17.8, 18.0, 18.6, 19.1, 20.6, 22.6, 22.9, and 28.4.

[00116] One embodiment provides a composition wherein the crystalline Form G of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the differential scanning calorimetry pattern as shown in Figure 33.

[00117] One embodiment provides a composition wherein the crystalline Form G of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the thermogravimetric analysis pattern as shown in Figure 34.

[00118] Provided herein is the crystalline solid Form H of 5-{[(2S,5R)-2,5-dimethyl-4-

(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-

6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-am ine.

[00119] One embodiment provides a composition wherein the crystalline Form H of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the X-ray powder diffraction pattern as shown in Figure 35. [00120] Provided herein is a composition comprising crystalline Form H of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine characterized by an X-ray diffraction pattern reflection at a 2 theta value of 4.4.

[00121] One embodiment provides a composition wherein the crystalline Form H is further characterized by X-ray diffraction pattern reflections at 2 theta values of 12.6, 12.9, 13.1, 14.1, 16.7, 17.7, 18.1, and 18.9.

[00122] One embodiment provides a composition wherein the crystalline Form H is further characterized by X-ray diffraction pattern reflections at 2 theta values of 3.1, 3.7, 4.9, 5.3, 10.0, 11.1, 13.3, 15.3, 17.5, 22.3, and 25.2.

[00123] One embodiment provides a composition wherein the crystalline Form H is further characterized by at least one X-ray diffraction pattern reflection selected from a 2 theta value of 3.1, 3.7, 4.4, 4.9, 5.3, 10.0, 11.1, 12.6, 12.9, 13.1, 13.3, 14.1, 15.3, 16.7, 17.5, 17.7, 18.1, 18.9, 22.3, and 25.2.

[00124] One embodiment provides a composition wherein the crystalline Form H is further characterized by at least two X-ray diffraction pattern reflection selected from a 2 theta value of 3.1, 3.7, 4.4, 4.9, 5.3, 10.0, 11.1, 12.6, 12.9, 13.1, 13.3, 14.1, 15.3, 16.7, 17.5, 17.7, 18.1, 18.9, 22.3, and 25.2.

[00125] One embodiment provides a composition wherein the crystalline Form H is further characterized by at least three X-ray diffraction pattern reflection selected from a 2 theta value of 3.1, 3.7, 4.4, 4.9, 5.3, 10.0, 11.1, 12.6, 12.9, 13.1, 13.3, 14.1, 15.3, 16.7, 17.5, 17.7, 18.1, 18.9, 22.3, and 25.2.

[00126] One embodiment provides a composition wherein the crystalline Form H is further characterized by at least four X-ray diffraction pattern reflection selected from a 2 theta value of 3.1, 3.7, 4.4, 4.9, 5.3, 10.0, 11.1, 12.6, 12.9, 13.1, 13.3, 14.1, 15.3, 16.7, 17.5, 17.7, 18.1, 18.9, 22.3, and 25.2.

[00127] One embodiment provides a composition wherein the crystalline Form H is further characterized by at least five X-ray diffraction pattern reflection selected from a 2 theta value of 3.1, 3.7, 4.4, 4.9, 5.3, 10.0, 11.1, 12.6, 12.9, 13.1, 13.3, 14.1, 15.3, 16.7, 17.5, 17.7, 18.1, 18.9, 22.3, and 25.2.

[00128] One embodiment provides a composition wherein the crystalline Form H is further characterized by at least six X-ray diffraction pattern reflection selected from a 2 theta value of 3.1 , 3.7, 4.4, 4.9, 5.3, 10.0, 11.1, 12.6, 12.9, 13.1, 13.3, 14.1, 15.3, 16.7, 17.5, 17.7, 18.1, 18.9, 22.3, and 25.2. [00129] One embodiment provides a composition wherein the crystalline Form H of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the differential scanning calorimetry pattern as shown in Figure 37.

[00130] One embodiment provides a composition wherein the crystalline Form H of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the thermogravimetric analysis pattern as shown in Figure 38.

[00131] Provided herein is the crystalline solid Form I of 5-{[(2S,5R)-2,5-dimethyl-4-

(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-

6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-am ine.

[00132] One embodiment provides a composition wherein the crystalline Form I of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the X-ray powder diffraction pattern as shown in Figure 39.

[00133] Provided herein is a composition comprising crystalline Form I of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine characterized by an X-ray diffraction pattern reflection at a 2 theta value of 15.7.

[00134] One embodiment provides a composition wherein the crystalline Form I is further characterized by X-ray diffraction pattern reflections at 2 theta values of 8.8, 10.0, 10.5, 11.5, 12.4,

13.4, 16.3, 16.4, 17.6, and 22.0.

[00135] One embodiment provides a composition wherein the crystalline Form I is further characterized by X-ray diffraction pattern reflections at 2 theta values of 5.5, 11.0, 17.2, 19.3, 19.9, 21.3, 23.1, 23.5, and 25.0.

[00136] One embodiment provides a composition wherein the crystalline Form I is further characterized by at least one X-ray diffraction pattern reflection selected from a 2 theta value of 5.5, 8.8, 10.0, 10.5, 11.0, 11.5, 12.4, 13.4, 15.7, 16.3, 16.4, 17.2, 17.6, 19.3, 19.9, 21.3, 22.0, 23.1,

23.5, and 25.0.

[00137] One embodiment provides a composition wherein the crystalline Form I is further characterized by at least two X-ray diffraction pattern reflection selected from a 2 theta value of 5.5, 8.8, 10.0, 10.5, 11.0, 11.5, 12.4, 13.4, 15.7, 16.3, 16.4, 17.2, 17.6, 19.3, 19.9, 21.3, 22.0, 23.1, 23.5, and 25.0. [00138] One embodiment provides a composition wherein the crystalline Form I is further characterized by at least three X-ray diffraction pattern reflection selected from a 2 theta value of 5.5, 8.8, 10.0, 10.5, 11.0, 11.5, 12.4, 13.4, 15.7, 16.3, 16.4, 17.2, 17.6, 19.3, 19.9, 21.3, 22.0, 23.1, 23.5, and 25.0.

[00139] One embodiment provides a composition wherein the crystalline Form I is further characterized by at least four X-ray diffraction pattern reflection selected from a 2 theta value of 5.5, 8.8, 10.0, 10.5, 11.0, 11.5, 12.4, 13.4, 15.7, 16.3, 16.4, 17.2, 17.6, 19.3, 19.9, 21.3, 22.0, 23.1, 23.5, and 25.0.

[00140] One embodiment provides a composition wherein the crystalline Form I is further characterized by at least five X-ray diffraction pattern reflection selected from a 2 theta value of 5.5, 8.8, 10.0, 10.5, 11.0, 11.5, 12.4, 13.4, 15.7, 16.3, 16.4, 17.2, 17.6, 19.3, 19.9, 21.3, 22.0, 23.1, 23.5, and 25.0.

[00141] One embodiment provides a composition wherein the crystalline Form I is further characterized by at least six X-ray diffraction pattern reflection selected from a 2 theta value of 5.5, 8.8, 10.0, 10.5, 11.0, 11.5, 12.4, 13.4, 15.7, 16.3, 16.4, 17.2, 17.6, 19.3, 19.9, 21.3, 22.0, 23.1, 23.5, and 25.0.

[00142] One embodiment provides a composition wherein the crystalline Form I of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the differential scanning calorimetry pattern as shown in Figure 41.

[00143] One embodiment provides a composition wherein the crystalline Form I of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine exhibits the thermogravimetric analysis pattern as shown in Figure 42.

[00144] Provided herein is the maleate salt of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine.

[00145] Provided herein is the fumarate salt of 5-{ [(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine.

[00146] Provided herein is the compound 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-

4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2-methylpyrimidin-4-yl)-6, 6-dimethyl- 1 ,4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone. Provided herein is the compound 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, essentially free of bis(3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[ 3,4-c]pyrazol-5(lH)-yl)methanone.

[00147] Provided herein is the compound 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-

4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2-methylpyrimidin-4-yl)-6, 6-dimethyl- 1 ,4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, substantially free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone. One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 1 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.5 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.4 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.3 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.25 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.20 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.15 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.10 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.08 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.05 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is not more than 1 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.5 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.4 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)- 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)metha none is not more than 0.3 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH )-yl)methanone is not more than 0.25 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[ 3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.20 % (w/w). One embodiment provides a composition wherein the bis(3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-4,6-dihydr opyrrolo[3,4-c]pyrazol-5(lH)- yl)methanone is not more than 0.15 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is not more than 0.10 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.08 % (w/w). One

embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)- 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)metha none is not more than 0.05 % (w/w).

[00148] Provided herein is the compound 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-

4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2-methylpyrimidin-4-yl)-6, 6-dimethyl- 1 ,4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate. Provided herein is the compound 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, essentially free of ethyl 5-((2S,5R)- 2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine- l-carbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate. [00149] Provided herein is the compound 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-

4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2-methylpyrimidin-4-yl)-6, 6-dimethyl- 1 ,4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, substantially free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate. One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 1 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4 H)-carboxylate, and ethyl 5- ((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)pi perazine-l-carbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-l(4H)-carboxylate are each less than 0.5 % (w/w). One embodiment provides a composition wherein the ethyl 5- ((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)pi perazine-l-carbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.4 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.3 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 0.25 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.20 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.15 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 0.10 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.08 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.05 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 1 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydro^

and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.5 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each not more than 0.4 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.3 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.25 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate are each not more than 0.20 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H- pyran-4-yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-meth ylpyrimidin-4-yl)amino)-6,6- dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate , and ethyl 5-((2S,5R)-2,5-dimethyl- 4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3 -((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.15 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole carboxylate are each not more than 0.10 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate are each not more than 0.08 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H- pyran-4-yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-meth ylpyrimidin-4-yl)amino)-6,6- dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate , and ethyl 5-((2S,5R)-2,5-dimethyl- 4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3 -((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.05 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are not detectable.

[00150] Provided herein is the compound 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-

4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2-methylpyrimidin-4-yl)-6, 6-dimethyl- 1 ,4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, free of impurities. In some embodiments, the compound is free of structurally related impurities. Provided herein is the compound 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, essentially free of impurities. In some embodiments, the compound is essentially free of structurally related impurities.

[00151] Provided herein is the compound 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-

4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2-methylpyrimidin-4-yl)-6, 6-dimethyl- 1 ,4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine or a pharmaceutically acceptable salt, solution or hydrate thereof, substantially free of impurities. In some embodiments, the compound is substantially free of structurally related impurities. One embodiment provides a composition wherein the amount of impurities is less than 1 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of impurities is not detectable.

[00152] One embodiment provides a composition wherein substantially free means less than about 10 % (w/w), less than about 9 % (w/w), less than about 8 % (w/w), less than about 7 % (w/w), less than about 6 % (w/w), less than about 5 % (w/w), less than about 4.75 % (w/w), less than about 4.5 % (w/w), less than about 4.25 % (w/w), less than about 4 % (w/w), less than about 3.75 % (w/w), less than about 3.5 % (w/w), less than about 3.25 % (w/w), less than about 3 % (w/w), less than about 2.75 % (w/w), less than about 2.5 % (w/w), less than about 2.25 % (w/w), less than about 2 % (w/w), less than about 1.75 % (w/w), less than about 1.5 % (w/w), less than about 1.25 % (w/w), less than about 1 % (w/w), less than about 0.9 % (w/w), less than about 0.8 % (w/w), less than about 0.7 % (w/w), less than about 0.6 % (w/w), less than about 0.5 % (w/w), less than about 0.4 % (w/w), less than about 0.3 % (w/w), less than about 0.25 % (w/w), less than about 0.20 % (w/w), less than about 0.15 % (w/w), less than about 0.1 % (w/w), less than about 0.08 % (w/w), or less than about 0.05 % (w/w). One embodiment provides a composition wherein substantially free means an undetectable amount. One embodiment provides a composition wherein substantially free means less than about 5 % (w/w), less than about 3 % (w/w), less than about 1 % (w/w), less than about 0.5 % (w/w), or less than about 0.2 % (w/w).

Amorphous Solid Form

[00153] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4-c]pyrazol- 5(lH)-yl)methanone. Provided herein is a composition wherein the amorphous solid form of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is essentially free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone.

[00154] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is substantially free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone. One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 1 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.5 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.4 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.3 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.25 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.20 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.15 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.10 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.08 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.05 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is not more than 1 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.5 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.4 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)- 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)metha none is not more than 0.3 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH )-yl)methanone is not more than 0.25 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[ 3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.20 % (w/w). One embodiment provides a composition wherein the bis(3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-4,6-dihydr opyrrolo[3,4-c]pyrazol-5(lH)- yl)methanone is not more than 0.15 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is not more than 0.10 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.08 % (w/w). One

embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)- 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)metha none is not more than 0.05 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin- 4-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5( lH)-yl)methanone is not detectable.

[00155] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate. Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6 etrahydropyrrolo[3,4-c]pyrazol-3-amine is essentially free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine- l-carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-d imethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate.

[00156] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is substantially free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate. One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 1 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4 H)-carboxylate, and ethyl 5- ((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)pi perazine-l-carbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-l(4H)-carboxylate are each less than 0.5 % (w/w). One embodiment provides a composition wherein the ethyl 5- ((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)pi perazine-l-carbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.4 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,^ c]pyrazole-l(4H)-carboxylate are each less than 0.3 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 0.25 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.20 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.15 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 0.10 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.08 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.05 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 1 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.5 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each not more than 0.4 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.3 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.25 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate are each not more than 0.20 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H- pyran-4-yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-meth ylpyrimidin-4-yl)amino)-6,6- dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate , and ethyl 5-((2S,5R)-2,5-dimethyl- 4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3 -((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.15 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.10 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate are each not more than 0.08 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H- pyran-4-yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-meth ylpyrimidin-4-yl)amino)-6,6- dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate , and ethyl 5-((2S,5R)-2,5-dimethyl- 4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3 -((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.05 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are not detectable.

[00157] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is free of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine. Provided herein is a composition wherein the amorphous solid form of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is essentially free of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluo

tetrahydropyrrolo[3,4-c]pyrazol-3-amine.

[00158] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is substantially free of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine. One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 1 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)pipera

6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is not detectable.

[00159] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is free of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine. Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is essentially free of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine .

[00160] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is substantially free of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine. One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 1 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3 -amine is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not detectable. One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not detectable in its X-ray diffraction pattern.

[00161] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is free of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine. Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l-l,4,5,6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is essentially free of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine .

[00162] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is substantially free of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine. One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 1 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not detectable. One embodiment provides a composition wherein the amount of crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not detectable in its X-ray diffraction pattern.

[00163] Provided herein is a composition of the amorphous solid form of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine wherein the X-ray diffraction pattern has no detectable reflections. One embodiment provides a composition whose X-ray diffraction pattern does not have a reflection at a 2 theta value of 16.3. One embodiment provides a composition whose X-ray diffraction pattern does not have a reflection at a 2 theta value of 17.3. One embodiment provides a composition whose X-ray diffraction pattern does not have a reflection at a 2 theta value of 17.9. One embodiment provides a composition whose X-ray diffraction pattern does not have a reflection at a 2 theta value of 18.1.

[00164] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is free of impurities. In some embodiments, the composition is free of structurally related impurities.

Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is essentially free of impurities. In some embodiments, the composition is essentially free of structurally related impurities.

[00165] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is substantially free of impurities. In some embodiments, the composition is substantially free of structurally related impurities. One embodiment provides a composition wherein the amount of impurities is less than 1 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of impurities is not detectable.

[00166] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is substantially free of solvent. One embodiment provides a composition wherein the amount of solvent is less than 20 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 15 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 10 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 5 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 20 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 15 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 10 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 5 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 2.0 equivalents. One embodiment provides a

composition wherein the amount of solvent is less than 1.5 equivalents. One embodiment provides a composition wherein the amount of solvent is less than 1.0 equivalent. One embodiment provides a composition wherein the amount of solvent is not more than 2.0 equivalents. One embodiment provides a composition wherein the amount of solvent is not more than 1.5 equivalents. One embodiment provides a composition wherein the amount of solvent is not more than 1.0 equivalent.

[00167] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is

substantially free of water. One embodiment provides a composition wherein the amount of water is less than 20 % (w/w). One embodiment provides a composition wherein the amount of water is less than 15 % (w/w). One embodiment provides a composition wherein the amount of water is less than 10 % (w/w). One embodiment provides a composition wherein the amount of water is less than 7.5 % (w/w). One embodiment provides a composition wherein the amount of water is less than 7.0 % (w/w). One embodiment provides a composition wherein the amount of water is less than 6.5 % (w/w). One embodiment provides a composition wherein the amount of water is less than 6.0 % (w/w). One embodiment provides a composition wherein the amount of water is less than 5.5 % (w/w). One embodiment provides a composition wherein the amount of water is less than 5.0 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 20 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 15 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 10 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 7.5 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 7.0 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 6.5 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 6.0 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 5.5 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 5.0 % (w/w). One embodiment provides a composition wherein the amount of water is less than 2.0 equivalents. One embodiment provides a composition wherein the amount of water is less than 1.5 equivalents. One embodiment provides a composition wherein the amount of water is less than 1.0 equivalent. One embodiment provides a composition wherein the amount of water is not more than 2.0 equivalents. One embodiment provides a composition wherein the amount of water is not more than 1.5 equivalents. One embodiment provides a composition wherein the amount of water is not more than 1.0 equivalent.

[00168] Provided herein is a composition wherein the amorphous solid form of 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine comprises a small amount of water. One embodiment provides a composition wherein the amount of water is from 1.5 % (w/w) to 7.0 % (w/w) of water. One embodiment provides a composition wherein the amount of water is from 2.0 % (w/w) to 6.0 % (w/w One embodiment provides a composition wherein the amount of water is from 2.2 % (w/w) to 5.9 % (w/w). One embodiment provides a composition wherein the amount of water is from 2.4 % (w/w) to 5.8 % (w/w). One embodiment provides a composition wherein the amount of water is from 2.5 % (w/w) to 5.7 % (w/w). One embodiment provides a composition wherein the amount of water is from 2.7 % (w/w) to 5.5 % (w/w). One embodiment provides a composition wherein the amount of water is from 0.25 equivalents to 3.0 equivalents. One embodiment provides a composition wherein the amount of water is from 0.5 equivalents to 2.5 equivalents. One embodiment provides a composition wherein the amount of water is from 0.75 equivalents to 2.25 equivalents. One embodiment provides a composition wherein the amount of water is from 1.0 equivalent to 2.0 equivalents.

Crystalline Hydrate Form B

[00169] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4-c]pyrazol- 5(lH)-yl)methanone. Provided herein is a composition wherein the crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is essentially free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone.

[00170] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone. One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 1 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.5 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.4 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.3 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.25 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.20 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.15 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.10 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.08 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.05 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is not more than 1 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.5 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.4 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)- 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)metha none is not more than 0.3 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH )-yl)methanone is not more than 0.25 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[ 3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.20 % (w/w). One embodiment provides a composition wherein the bis(3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim

yl)methanone is not more than 0.15 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is not more than 0.10 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.08 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)- 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)metha none is not more than 0.05 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin- 4-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5( lH)-yl)methanone is not detectable.

[00171] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate. Provided herein is a composition wherein the crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is essentially free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate.

[00172] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate. One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyri

dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 1 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4 H)-carboxylate, and ethyl 5- ((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)pi perazine-l-carbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-l(4H)-carboxylate are each less than 0.5 % (w/w). One embodiment provides a composition wherein the ethyl 5- ((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)pi perazine-l-carbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.4 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.3 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 0.25 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.20 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,^ c]pyrazole-l(4H)-carboxylate are each less than 0.15 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 0.10 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.08 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.05 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 1 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.5 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each not more than 0.4 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.3 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.25 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate are each not more than 0.20 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H- pyran-4-yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-meth ylpyrimidin-4-yl)amino)-6,6- dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate , and ethyl 5-((2S,5R)-2,5-dimethyl- 4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3 -((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.15 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.10 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate are each not more than 0.08 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H- pyran-4-yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-meth ylpyrimidin-4-yl)amino)-6,6- dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate , and ethyl 5-((2S,5R)-2,5-dimethyl- 4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3 -((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.05 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are not detectable.

[00173] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is free of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine. Provided herein is a composition wherein the crystalline hydrate Form B of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is essentially free of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine.

[00174] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine. One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 1 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dim l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is not detectable.

[00175] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is free of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine. Provided herein is a composition wherein the crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is essentially free of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)pipera

6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-am ine.

[00176] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine. One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 1 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethy l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not detectable.

[00177] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is free of impurities. In some embodiments, the composition is free of structurally related impurities.

Provided herein is a composition wherein crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl- 4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N -(5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is essentially free of impurities. In some embodiments, the composition is essentially free of structurally related impurities.

[00178] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of impurities. In some embodiments, the composition is substantially free of structurally related impurities. One embodiment provides a composition wherein the amount of impurities is less than 1 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of impurities is not detectable.

[00179] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of solvent. One embodiment provides a composition wherein the amount of solvent is less than 20 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 15 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 10 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 5 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 20 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 15 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 10 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 5 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 2.0 equivalents. One embodiment provides a

composition wherein the amount of solvent is less than 1.5 equivalents. One embodiment provides a composition wherein the amount of solvent is less than 1.0 equivalent. One embodiment provides a composition wherein the amount of solvent is not more than 2.0 equivalents. One embodiment provides a composition wherein the amount of solvent is not more than 1.5 equivalents. One embodiment provides a composition wherein the amount of solvent is not more than 1.0 equivalent.

[00180] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of water. One embodiment provides a composition wherein the amount of water is less than 20 % (w/w). One embodiment provides a composition wherein the amount of water is less than 15 % (w/w). One embodiment provides a composition wherein the amount of water is less than 10 % (w/w). One embodiment provides a composition wherein the amount of water is less than 7.5 % (w/w). One embodiment provides a composition wherein the amount of water is less than 7.0 % (w/w). One embodiment provides a composition wherein the amount of water is less than 6.5 % (w/w). One embodiment provides a composition wherein the amount of water is less than 6.0 % (w/w). One embodiment provides a composition wherein the amount of water is less than 5.5 % (w/w). One embodiment provides a composition wherein the amount of water is less than 5.0 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 20 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 15 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 10 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 7.5 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 7.0 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 6.5 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 6.0 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 5.5 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 5.0 % (w/w). One embodiment provides a composition wherein the amount of water is less than 2.0 equivalents. One embodiment provides a composition wherein the amount of water is less than 1.5 equivalents. One embodiment provides a composition wherein the amount of water is less than 1.0 equivalent. One embodiment provides a composition wherein the amount of water is not more than 2.0 equivalents. One embodiment provides a composition wherein the amount of water is not more than 1.5 equivalents. One embodiment provides a composition wherein the amount of water is not more than 1.0 equivalent.

Crystalline Hydrate Form D

[00181] Provided herein is a composition wherein the crystalline hydrate Form D of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4-c]pyrazol- 5(lH)-yl)methanone. Provided herein is a composition wherein the crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is essentially free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone. [00182] Provided herein is a composition wherein the crystalline hydrate Form D of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone. One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 1 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.5 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.4 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.3 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.25 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.20 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.15 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.10 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.08 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.05 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is not more than 1 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.5 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.4 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)- 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)metha none is not more than 0.3 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH )-yl)methanone is not more than 0.25 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[ 3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.20 % (w/w). One embodiment provides a composition wherein the bis(3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-4,6-dihydr opyrrolo[3,4-c]pyrazol-5(lH)- yl)methanone is not more than 0.15 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is not more than 0.10 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.08 % (w/w). One

embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)- 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)metha none is not more than 0.05 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin- 4-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5( lH)-yl)methanone is not detectable.

[00183] Provided herein is a composition wherein the crystalline hydrate Form D of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate. Provided herein is a composition wherein the crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is essentially free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate.

[00184] Provided herein is a composition wherein the crystalline hydrate Form D of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate. One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 1 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4 H)-carboxylate, and ethyl 5- ((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)pi perazine-l-carbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-l(4H)-carboxylate are each less than 0.5 % (w/w). One embodiment provides a composition wherein the ethyl 5- ((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)pi perazine-l-carbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.4 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.3 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 0.25 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.20 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.15 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 0.10 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.08 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.05 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 1 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.5 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each not more than 0.4 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.3 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.25 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate are each not more than 0.20 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H- pyran-4-yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-meth ylpyrimidin-4-yl)amino)-6,6- dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate , and ethyl 5-((2S,5R)-2,5-dimethyl- 4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3 -((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.15 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.10 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate are each not more than 0.08 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H- pyran-4-yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-meth ylpyrimidin-4-yl)amino)-6,6- dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate , and ethyl 5-((2S,5R)-2,5-dimethyl- 4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3 -((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.05 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are not detectable.

[00185] Provided herein is a composition wherein the crystalline hydrate Form D of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is free of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine. Provided herein is a composition wherein the crystalline hydrate Form B of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is essentially free of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine.

[00186] Provided herein is a composition wherein the crystalline hydrate Form B of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine. One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 1 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dim l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is not detectable.

[00187] Provided herein is a composition wherein the crystalline hydrate Form D of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is free of impurities. In some embodiments, the composition is free of structurally related impurities.

Provided herein is a composition wherein crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl- 4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N -(5-fluoro-2-methylpyrimidin-4- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is essentially free of impurities. In some embodiments, the composition is essentially free of structurally related impurities.

[00188] Provided herein is a composition wherein the crystalline hydrate Form D of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of impurities. In some embodiments, the composition is substantially free of structurally related impurities. One embodiment provides a composition wherein the amount of impurities is less than 1 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of impurities is not detectable.

[00189] Provided herein is a composition wherein the crystalline hydrate Form D of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of solvent. One embodiment provides a composition wherein the amount of solvent is less than 20 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 15 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 10 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 5 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 20 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 15 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 10 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 5 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 2.0 equivalents. One embodiment provides a

composition wherein the amount of solvent is less than 1.5 equivalents. One embodiment provides a composition wherein the amount of solvent is less than 1.0 equivalent. One embodiment provides a composition wherein the amount of solvent is not more than 2.0 equivalents. One embodiment provides a composition wherein the amount of solvent is not more than 1.5 equivalents. One embodiment provides a composition wherein the amount of solvent is not more than 1.0 equivalent.

[00190] Provided herein is a composition wherein the crystalline hydrate Form D of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is substantially free of water. One embodiment provides a composition wherein the amount of water is less than 20 % (w/w). One embodiment provides a composition wherein the amount of water is less than 15 % (w/w). One embodiment provides a composition wherein the amount of water is less than 10 % (w/w). One embodiment provides a composition wherein the amount of water is less than 7.5 % (w/w). One embodiment provides a composition wherein the amount of water is less than 7.0 % (w/w). One embodiment provides a composition wherein the amount of water is less than 6.5 % (w/w). One embodiment provides a composition wherein the amount of water is less than 6.0 % (w/w). One embodiment provides a composition wherein the amount of water is less than 5.5 % (w/w). One embodiment provides a composition wherein the amount of water is less than 5.0 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 20 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 15 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 10 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 7.5 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 7.0 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 6.5 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 6.0 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 5.5 % (w/w). One embodiment provides a composition wherein the amount of water is not more than 5.0 % (w/w). One embodiment provides a composition wherein the amount of water is less than 2.0 equivalents. One embodiment provides a composition wherein the amount of water is less than 1.5 equivalents. One embodiment provides a composition wherein the amount of water is less than 1.0 equivalent. One embodiment provides a composition wherein the amount of water is not more than 2.0 equivalents. One embodiment provides a composition wherein the amount of water is not more than 1.5 equivalents. One embodiment provides a composition wherein the amount of water is not more than 1.0 equivalent.

Crystalline 2-Propanol Solvate Form A

[00191] Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone. Provided herein is a composition wherein the crystalline 2- propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is essentially free of bis(3-((5-fluoro-2-methylpyrimidin- 4-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5( lH)-yl)methanone.

[00192] Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is substantially free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone. One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 1 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.5 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.4 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.3 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.25 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.20 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.15 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.10 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.08 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is less than 0.05 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is not more than 1 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.5 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.4 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)- 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)metha none is not more than 0.3 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH )-yl)methanone is not more than 0.25 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[ 3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.20 % (w/w). One embodiment provides a composition wherein the bis(3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-4,6-dihydr opyrrolo[3,4-c]pyrazol-5(lH)- yl)methanone is not more than 0.15 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4- c]pyrazol-5(lH)-yl)methanone is not more than 0.10 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone is not more than 0.08 % (w/w). One

embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)- 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)metha none is not more than 0.05 % (w/w). One embodiment provides a composition wherein the bis(3-((5-fluoro-2-methylpyrimidin- 4-yl)amino)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5( lH)-yl)methanone is not detectable. [00193] Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)- 3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole- 2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate. Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is essentially free of ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4 H)-carboxylate, and ethyl 5- ((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)pi perazine-l-carbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-l(4H)-carboxylate.

[00194] Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is substantially free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate. One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 1 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4 H)-carboxylate, and ethyl 5- ((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)pi perazine-l-carbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-l(4H)-carboxylate are each less than 0.5 % (w/w). One embodiment provides a composition wherein the ethyl 5- ((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)pi perazine-l-carbonyl)-3-((5-fluoro-2^ methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.4 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.3 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 0.25 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.20 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.15 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each less than 0.10 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each less than 0.08 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each less than 0.05 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 1 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.5 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate are each not more than 0.4 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.3 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.25 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate are each not more than 0.20 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H- pyran-4-yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-meth ylpyrimidin-4-yl)amino)-6,6- dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate , and ethyl 5-((2S,5R)-2,5-dimethyl- 4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3 -((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.15 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are each not more than 0.10 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate are each not more than 0.08 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H- pyran-4-yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-meth ylpyrimidin-4-yl)amino)-6,6- dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate , and ethyl 5-((2S,5R)-2,5-dimethyl- 4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3 -((5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate are each not more than 0.05 % (w/w). One embodiment provides a composition wherein the ethyl 5-((2S,5R)-2,5- dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-ca rbonyl)-3-((5-fluoro-2- methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[ 3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3- ((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-di hydropyrrolo[3,4-c]pyrazole-l(4H)- carboxylate are not detectable. [00195] Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is free of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine. Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is essentially free of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine.

[00196] Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is substantially free of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine. One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 1 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro- 2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-m ethylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of other solid forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine is not detectable.

[00197] Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is free of impurities. In some embodiments, the composition is free of structurally related impurities. Provided herein is a composition wherein crystalline 2-propanol solvate Form A of 5-{[(2S,5R)- 2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is essentially free of impurities. In some embodiments, the composition is essentially free of structurally related impurities.

[00198] Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is substantially free of impurities. In some embodiments, the composition is substantially free of structurally related impurities. One embodiment provides a composition wherein the amount of impurities is less than 1 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.5 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.4 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.3 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.25 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.20 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.15 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.10 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.08 % (w/w). One embodiment provides a composition wherein the amount of impurities is less than 0.05 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 1 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.5 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.4 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.3 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.25 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.20 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.15 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.10 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.08 % (w/w). One embodiment provides a composition wherein the amount of impurities is not more than 0.05 % (w/w). One embodiment provides a composition wherein the amount of impurities is not detectable.

[00199] Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is substantially free of solvent. One embodiment provides a composition wherein the amount of solvent is less than 20 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 15 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 10 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 5 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 20 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 15 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 10 % (w/w). One embodiment provides a composition wherein the amount of solvent is not more than 5 % (w/w). One embodiment provides a composition wherein the amount of solvent is less than 2.0 equivalents. One embodiment provides a

composition wherein the amount of solvent is less than 1.5 equivalents. One embodiment provides a composition wherein the amount of solvent is less than 1.0 equivalent. One embodiment provides a composition wherein the amount of solvent is not more than 2.0 equivalents. One embodiment provides a composition wherein the amount of solvent is not more than 1.5 equivalents. One embodiment provides a composition wherein the amount of solvent is not more than 1.0 equivalent.

[00200] Provided herein is a composition wherein the crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is substantially free of 2-propanol. One embodiment provides a composition wherein the amount of 2-propanol is less than 20 % (w/w). One embodiment provides a composition wherein the amount of 2-propanol is less than 15 % (w/w). One embodiment provides a composition wherein the amount of 2-propanol is less than 10 % (w/w). One embodiment provides a composition wherein the amount of 2-propanol is less than 5 % (w/w). One embodiment provides a composition wherein the amount of 2-propanol is not more than 20 % (w/w). One embodiment provides a composition wherein the amount of 2-propanol is not more than 15 % (w/w). One embodiment provides a composition wherein the amount of 2-propanol is not more than 10 % (w/w). One embodiment provides a composition wherein the amount of 2-propanol is not more than 5 % (w/w). One embodiment provides a composition wherein the amount of 2-propanol is less than 2.0 equivalents. One embodiment provides a composition wherein the amount of 2-propanol is less than 1.5 equivalents. One embodiment provides a composition wherein the amount of 2-propanol is less than 1.0 equivalent. One embodiment provides a composition wherein the amount of 2-propanol is not more than 2.0 equivalents. One embodiment provides a composition wherein the amount of 2- propanol is not more than 1.5 equivalents. One embodiment provides a composition wherein the amount of 2-propanol is not more than 1.0 equivalent.

Pharmaceutical Compositions

[00201] Provided herein is a pharmaceutical composition comprising 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine, and one or more pharmaceutically acceptable excipients or carriers. Also provided herein is a pharmaceutical composition comprising 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof. [00202] Provided herein is a pharmaceutical composition comprising an amorphous solid of

5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethy l)piperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine and one or more pharmaceutically acceptable excipients or carriers. Also provided herein is a pharmaceutical composition comprising an amorphous solid of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.

[00203] Provided herein is a pharmaceutical composition comprising the maleate salt of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the

pharmaceutical composition comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.

[00204] Provided herein is a pharmaceutical composition comprising the fumarate salt of 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the

pharmaceutical composition comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.

[00205] Provided herein is a pharmaceutical composition comprising crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine and one or more pharmaceutically acceptable excipients or carriers. Also provided herein is a pharmaceutical composition comprising crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.

[00206] Provided herein is a pharmaceutical composition comprising crystalline hydrate

Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6 etrahydropyrrolo[3,4-c]pyrazol-3- amine and one or more pharmaceutically acceptable excipients or carriers. Also provided herein is a pharmaceutical composition comprising crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl- 4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N -(5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.

[00207] Provided herein is a pharmaceutical composition comprising crystalline hydrate

Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine and one or more pharmaceutically acceptable excipients or carriers. Also provided herein is a pharmaceutical composition comprising crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl- 4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N -(5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.

[00208] Provided herein is a pharmaceutical composition comprising crystalline hydrate

Form L of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine and one or more pharmaceutically acceptable excipients or carriers. Also provided herein is a pharmaceutical composition comprising crystalline hydrate Form L of 5-{ [(2S,5R)-2,5-dimethyl- 4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N -(5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.

[00209] Provided herein is a pharmaceutical composition comprising crystalline solid Form

G of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine and one or more pharmaceutically acceptable excipients or carriers. Also provided herein is a pharmaceutical composition comprising crystalline solid Form G of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.

[00210] Provided herein is a pharmaceutical composition comprising crystalline solid Form

H of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine and one or more pharmaceutically acceptable excipients or carriers. Also provided herein is a pharmaceutical composition comprising crystalline solid Form H of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.

[00211] Provided herein is a pharmaceutical composition comprising crystalline solid Form I of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine and one or more pharmaceutically acceptable excipients or carriers. Also provided herein is a pharmaceutical composition comprising crystalline solid Form I of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.

[00212] One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is free of impurities. In some embodiments, the composition is free of structurally related impurities. One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is essentially free of impurities. In some embodiments, the composition is essentially free of structurally related impurities. One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine is substantially free of impurities. In some embodiments, the composition is substantially free of structurally related impurities.

[00213] One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6-dihydropyrrolo[3,4-c]pyrazol- 5(lH)-yl)methanone. One embodiment provides a pharmaceutical composition, wherein the 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine is essentially free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone. One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin- l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimet hyl- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is substantially free of bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6- dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone .

[00214] One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine is free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l-carbonyl)-3-((5- fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl-5,6-dihydr opyrrolo[3,4-c]pyrazole-2(4H)- carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine-l- carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dim ethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-l(4H)-carboxylate. One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine is essentially free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine- l-carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-d imethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate. One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin- l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimet hyl- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine is substantially free of ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran- 4-yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyri midin-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-2(4H)-carboxylate, and ethyl 5-((2S,5R)-2,5-dimethyl-4- ((tetrahydro-2H-pyran-4-yl)methyl)piperazine-l-carbonyl)-3-( (5-fluoro-2-methylpyrimidin-4- yl)amino)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-l(4 H)-carboxylate.

[00215] One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine contains less than 20 % of solvent (w/w). One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine contains less than 15 % of solvent (w/w). One embodiment provides a pharmaceutical

composition, wherein the 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin- l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimet hyl- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine contains less than 10 % of solvent (w/w). One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine contains less than 5 % of solvent (w/w).

[00216] One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-

2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine contains less than 20 % of water (w/w). One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine contains less than 15 % of water (w/w). One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine contains less than 10 % of water (w/w). One embodiment provides a pharmaceutical composition, wherein the 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine contains less than 5 % of water (w/w).

[00217] Provided herein is a pharmaceutical compositions comprising any pharmaceutically acceptable salt of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine and one or more pharmaceutically acceptable excipients or carriers. In various embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.

[00218] Provided herein are pharmaceutical compositions in film-coated dosage forms, which comprise a combination of an active ingredient, and one or more tableting excipients to form a tablet core using conventional tableting processes and subsequently coating the core. The tablet cores can be produced using conventional granulation methods, for example wet or dry granulation, with optional comminution of the granules and with subsequent compression and coating.

[00219] The pharmaceutical compositions provided herein may be administered at once, or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations.

[00220] In the case wherein the patient's condition does not improve, upon the doctor's discretion the administration of the combinations may be administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition. In the case wherein the patient's status does improve, upon the doctor's discretion the administration of the combinations may be given continuously or temporarily suspended for a certain length of time {i.e., a "drug holiday"). In some embodiments, once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, can be reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained.

[00221] Treatment dosages generally may be titrated to optimize safety and efficacy.

Typically, dosage-effect relationships from in vitro studies initially can provide useful guidance on the proper doses for patient administration. Studies in animal models also generally may be used for guidance regarding effective dosages for treatment in accordance with the present disclosure. In terms of treatment protocols, it should be appreciated that the dosage to be administered will depend on several factors, including the particular agent that is administered, the route

administered, the condition of the particular patient, etc. Determination of these parameters is well within the skill of the art. These considerations, as well as effective formulations and

administration procedures are well known in the art and are described in standard textbooks. [00222] The pharmaceutical compositions provided herein are formulated in various dosage forms for oral administration. These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art {see, Remington: The Science and Practice of Pharmacy, Loyd V., Jr, Allen, Ed., Pharmaceutical Press.: New York, NY, 2002; Vol. 22).

[00223] As used herein, oral administration also include buccal, lingual, and sublingual administration. Suitable oral dosage forms include, but are not limited to, tablets, capsules, pills, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, granules, bulk powders, and effervescent or non-effervescent powders or granules. In addition to the active ingredient(s), the pharmaceutical compositions may contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, and flavoring agents. In some embodiments, the oral dosage form is a tablet, capsule, or pill.

[00224] In further embodiments, the pharmaceutical compositions provided herein may be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets.

Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach.

[00225] The tablet dosage forms may be prepared from the active ingredient in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and/or colorants. Flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.

[00226] The pharmaceutical compositions provided herein may be provided as soft or hard capsules, which can be made from gelatin, methyl cellulose, starch, or calcium alginate. The hard gelatin capsule, also known as the dry-filled capsule, consists of two sections, one slipping over the other, thus completely enclosing the active ingredient. The soft elastic capsule is a soft, globular shell, such as a gelatin shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The liquid, semisolid, and solid dosage forms provided herein may be encapsulated in a capsule. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides.

[00227] The term "therapeutically effective amount" or "effective amount" is an amount sufficient to effect beneficial or desired clinical results. An effective amount can be administered in one or more administrations. An effective amount is typically sufficient to palliate, ameliorate, stabilize, reverse, slow or delay the progression of the disease state.

[00228] The examples and preparations provided below further illustrate and exemplify the polymorphs of the present disclosure and methods of preparing such polymorphs. It is to be understood that the scope of the present disclosure is not limited in any way by the scope of the following examples and preparations.

[00229] The present disclosure relates to various solid state forms of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine and methods of making the same. Such forms of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine are useful in the treatment of cancer, immune disorders and inflammation. In one embodiment the various solid state forms of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine disclosed herein are useful for the treatment of inflammatory disorders such as uveitis.

Examples

[00230] The present disclosure is further illustrated by the following examples, which should not be construed as limiting in any way. The experimental procedures to generate the data shown are discussed in more detail below. The disclosure has been described in an illustrative manner, and it is to be understood that the terminology used is intended to be in the nature of description rather than of limitation.

General Experimental Details - Instrument and Methodology Details

X-Ray Powder Diffraction (XRPD)

[00231] X-Ray Powder Diffraction patterns were collected on a PANalytical diffractometer using Cu Ka radiation (45kV, 40mA), θ - Θ goniometer, focusing mirror, divergence slit (1/2"), soller slits at both incident and divergent beam (4mm) and a PIXcel detector. The software used for data collection was X'Pert Data Collector, version 2.2f and the data was presented using X'Pert Data Viewer, version 1.2d.

[00232] XRPD patterns were acquired under ambient conditions via a transmission foil sample stage (polyimide - Kapton, 12.7μπι thickness film) under ambient conditions using a PANalytical X'Pert PRO. The data collection range was 2.994 - 35°2Θ with a continuous scan speed of 0.202004°s ^"1 . Nuclear Magnetic Resonance (NMR)

[00233] 1H NMR spectra were collected using a JEOL EX 270 MHz spectrometer equipped with an auto-sampler. The samples were dissolved in a suitable deuterated solvent for analysis. The data was acquired using Delta NMR Processing and Control Software version 4.3.

Differential Scanning Calorimetry (DSC)

[00234] DSC data was collected on a PerkinElmer Pyris 4000 DSC equipped with a 45 position sample holder. The instrument was verified for energy and temperature calibration using certified indium. A predefined amount of the sample, 0.5-3.0 mg, was placed in a pin holed aluminum pan and heated at 20 °C min ^"1 from 30 to 350 °C, or varied as experimentation dictated. A purge of dry nitrogen at 60 mL min ^"1 was maintained over the sample. The instrument control, data acquisition and analysis was performed with Pyris Software v9.0.1.0203.

Therm o-Gravimetric Analysis (TGA)

[00235] TGA data were collected on a PerkinElmer Pyris 1 TGA equipped with a 20 position auto-sampler. The instrument was calibrated using a certified weight and certified Alumel and Perkalloy for temperature. A predefined amount of the sample, 1-5 mg, was loaded onto a pre- tared aluminium crucible and was heated at 20 °C min ^"1 from ambient temperature to 400 °C. A nitrogen purge at 20 mL min ^"1 was maintained over the sample. The instrument control, data acquisition and analysis was performed with Pyris Software v9.0.1.0203.

Infrared Spectroscopy

[00236] Data was collected on a Perkin Elmer Spectrum Two instrument with μATR Two accessory. The software used for data collection and presentation was Spectrum, version 10.03.08. A few grains < 1 mg of sample was compressed under a diamond tip for data collection.

Raman Spectroscopy

[00237] Raman spectra were collected on a PerkinElmer Raman Station 400. The software used for data collection and presentation was Spectrum, version 10.03.06. Raman spectra were acquired under ambient conditions with the sample presented on a glass microscope slide with Raman autofocus. The laser power was optimized as governed by the nature of the sample. The data collection range was 3400 to 200cm-l with an exposure time of 5-10 seconds at a data interval of lcm-1 over 10-30 accumulations as required for each sample.

Optical Microscopy

[00238] Optical microscopy examination was undertaken using a Leica DME polarized light microscope and an Infinity 1 digital video camera for image capture. A small amount of each sample was placed onto a glass slide and dispersed as best as possible. The samples were viewed with appropriate magnification and various images recorded. The image scale bar was calibrated against an external graticule, 0.1 mm/0.002 mm DIV.

Gravimetric Vapor Sorption (GVS)

[00239] Sorption isotherms were obtained using a Hiden Isochema moisture sorption analyzer (model IGAsorp), controlled by IGAsorp Systems Software V6.50.48. The sample was maintained at a constant temperature (25 °C) by the instrument controls. The humidity was controlled by mixing streams of dry and wet nitrogen, with a total flow of 250 mL min ^"1 . The instrument was verified for relative humidity content by measuring three calibrated Rotronic salt solutions (10 - 50 - 88 %). The weight change of the sample was monitored as a function of humidity by a microbalance (accuracy +/- 0.005 mg). A defined amount of sample was placed in a tared mesh stainless steel basket under ambient conditions. A full experimental cycle typically consisted of three scans (sorption, desorption and sorption) at a constant temperature (25 °C) and 10 % RH intervals over a 0 - 90 % range (60 minutes for each humidity level). This type of experiment should demonstrate the ability of samples studied to absorb moisture (or not) over a set of well-determined humidity ranges.

Chemical Purity Determination by HPLC

[00240] Purity analysis was performed on an Agilent 1 100 series liquid chromatograph.

Table 2 HPLC Method Parameters for Chemical Purity Determinations

Example 1: Processes for the synthesis of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran- 4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyri midin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine (Compound 1) [00241] A synthesis of Compound 1 was previously reported in WO 2008/096260.

Optimized synthetic routes to Compound 1 are presented below.

Scheme 1 - Synthesis of Compound 1

1C 8. Recrystallization with solvent Compound 1

[00242] A reaction vessel was charged with compound 1 A, compound IB, N,N- diisopropylethylamine and acetonitrile. The reaction was heated to 70-80 °C for approximately 6 hours. Following the cooling of the reaction mixture to room temperature, the acetonitrile solvent was removed and replaced with ethanol to afford a solution of 1C. The solution of 1C was subsequently charged with lithium hydroxide and heated to 40 °C for approximately 6 hours. The reaction solvent was then exchanged for ethyl acetate and washed with a solution of sodium bicarbonate. Ethyl acetate was removed as the solvent, and exchanged for acetonitrile. The solution was subsequently stirred at 70 °C for 2-4 hours. The solution was then allowed to cool, and was filtered to afford solid Compound 1. Recrystallization of Compound 1 using acetonitrile or 2- propanol followed by water slurry and drying served to purify Compound 1 and eliminate the presence of impurity bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-dimethyl- 4,6- dihydropyrrolo[3,4-c]pyrazol-5(lH)-yl)methanone (structure shown below), unreacted 1C (two carbamate isomers: ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methyl) piperazine- l-carbonyl)-3-((5-fluoro-2-methylpyrimidin-4-yl)amino)-6,6-d imethyl-5,6-dihydropyrrolo[3,4- c]pyrazole-2(4H)-carboxylate and ethyl 5-((2S,5R)-2,5-dimethyl-4-((tetrahydro-2H-pyran-4- yl)methyl)piperazine-l-carbonyl)-3-((5-fluoro-2-methylpyrimi din-4-yl)amino)-6,6-dimethyl-5,6- dihydropyrrolo[3,4-c]pyrazole-l(4H)-carboxylate), and other unidentified impurities. Following this purification process, Compound 1 exhibited a purity of greater than 99.8 % as determined by the analytical FIPLC method described in Table 2.

bis(3-((5-fluoro-2-methylpyrimidin-4-yl)amino)- 6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazol- 5(li/)-yl)methanone

Example 2: Process for the synthesis of amorphous solid 5-{[(2S,5R)-2,5-dimethyl-4-

(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4- yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-a mine

[00243] The crystalline hydrate of Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine was dried in a vacuum oven at 50-70 °C for 6-12 hours. The resulting solid exhibited the powder X-ray diffraction pattern displayed in Figure 1, and the DSC and TGA displayed in Figures 2a-2b.

Example 3: Process for the synthesis of a crystalline 2-propanol solvate Form A of 5- {[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pip erazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine

[00244] Following the final step of the procedure outlined in Scheme 1, recrystallization of Compound 1 from 2-propanol provided crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine.

Recrystallization was accomplished by dissolving 30 g of Compound 1 in 200 mL 2-propanol at 70-85 °C. Cooling the solution to 0-10 °C afforded crystalline material collected via filtration. Drying at 45 °C temperature for 5-10 hours yielded crystalline Form A in 64 % yield. The resulting solid exhibited the powder X-ray diffraction pattern displayed in Figures 3-4, and Table 3, the DSC and TGA displayed in Figures 5-6, and the infrared spectrum displayed in Figures 7-9.

Table 3. Peak listing for the X-ray powder diffractogram of crystalline 2-propanol solvate Form A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine

Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [A] Rel. Int. [%]

5.4553 218.33 0.5117 16.20011 L64

6.4698 570.19 0.0768 13.66181 4.27

6.7690 3089.14 0.1279 13.05877 23.14 8.9299 843.34 0.0512 9.90296 6.32

9.3883 158.50 0.0768 9.42042 1.19

12.9330 1058.45 0.0768 6.84533 7.93

13.6041 1007.70 0.0768 6.50910 7.55

15.3404 3812.12 0.1279 5.77607 28.55

15.6855 962.24 0.1023 5.64977 7.21

16.2965 433.60 0.1023 5.43930 3.25

16.9017 612.88 0.1023 5.24585 4.59

17.2342 2115.39 0.1279 5.14539 15.84

17.8950 1592.15 0.0768 4.95686 11.93

18.1461 13350.91 0.1023 4.88884 100.00

18.3845 1526.00 0.0768 4.82596 11.43

18.8431 637.53 0.0936 4.70563 4.78

18.9361 523.54 0.0768 4.68662 3.92

19.4872 1355.32 0.1279 4.55531 10.15

19.6110 1030.01 0.0768 4.52683 7.71

21.1904 915.90 0.1279 4.19286 6.86

21.6838 1108.16 0.1279 4.09856 8.30

22.1456 4612.68 0.1279 4.01412 34.55

22.4303 387.74 0.0768 3.96381 2.90

22.7827 1112.80 0.1279 3.90329 8.33

23.2781 167.09 0.1023 3.82133 1.25

23.6557 995.86 0.1023 3.76118 7.46

24.2423 260.14 0.1023 3.67148 1.95

24.5501 212.39 0.1023 3.62615 1.59

25.5948 77.56 0.1535 3.48046 0.58

26.4362 213.47 0.1535 3.37156 1.60

27.4602 472.93 0.1279 3.24812 3.54

28.4022 852.95 0.1535 3.14250 6.39

29.3038 35.14 0.3070 3.04784 0.26

30.2677 88.49 0.2047 2.95293 0.66

31.6879 110.80 0.2047 2.82375 0.83

32.2548 43.58 0.2558 2.77541 0.33

32.9883 208.05 0.1535 2.71535 1.56

33.3155 313.83 0.2047 2.68943 2.35

34.5977 122.72 0.1535 2.59264 0.92

Example 4: Process for the synthesis of crystalline hydrate Form B of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine [00245] Crystalline 2-propanol solvate Form A of 5-{ [(2S,5R)-2,5-dimethyl-4-(tetrahydro-

2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine (10 g) was suspended in 120 mL of water and stirred for 24 hours. The solid was isolated via filtration and dried under ambient conditions on the filter for 2 hours to afford the crystalline hydrate Form B of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine which exhibited the powder X-ray diffraction pattern displayed in Figures 10-11, and Table 4, the DSC and TGA displayed in Figures 12-13, the infrared spectrum displayed in Figure 14 and the Raman spectra displayed in Figures 15- 16.

Table 4. Peak listing for the X-ray powder diffractogram of crystalline hydrate Form B of 5- { [(2 S, 5R)-2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine

Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [A] Rel. Int. [%]

3.3999 421.69 0.0768 25.98791 11.93

5.5146 174.51 0.1535 16.02591 4.94

6.8414 784.32 0.0768 12.92058 22.19

7.3467 514.29 0.0768 12.03315 14.55

8.9999 2193.96 0.0768 9.82611 62.06

9.1700 1135.28 0.0512 9.64424 32.12

10.9295 2491.74 0.1279 8.09524 70.49

11.3063 994.88 0.1535 7.82631 28.14

12.1911 189.73 0.1023 7.26021 5.37

12.4074 234.16 0.1023 7.13411 6.62

13.7582 623.68 0.0768 6.43655 17.64

13.9555 723.13 0.1023 6.34602 20.46

14.2607 791.06 0.1023 6.21088 22.38

14.7640 1684.45 0.1023 6.00024 47.65

15.0050 2755.94 0.1023 5.90442 77.96

16.2619 3534.98 0.1279 5.45080 100.00

16.6330 730.39 0.0768 5.32999 20.66

16.8369 1014.46 0.1023 5.26590 28.70

17.0783 683.10 0.0768 5.19202 19.32

17.5325 316.45 0.1279 5.05853 8.95

18.0365 435.62 0.1791 4.91830 12.32

18.4002 348.00 0.1279 4.82189 9.84

18.6360 253.81 0.1023 4.76139 7.18 18.9462 130.97 0.1023 4.68414 3.71

19.3520 1499.85 0.1279 4.58683 42.43

20.0424 1882.77 0.1535 4.43036 53.26

20.3853 545.35 0.1023 4.35660 15.43

20.6123 513.60 0.1023 4.30913 14.53

21.5128 129.59 0.0768 4.13074 3.67

21.8602 417.75 0.1023 4.06588 11.82

22.1424 1512.60 0.1279 4.01469 42.79

22.6232 243.57 0.0768 3.93044 6.89

22.9842 1482.27 0.1279 3.86952 41.93

23.8435 306.35 0.0768 3.73198 8.67

24.1876 434.97 0.1023 3.67967 12.30

24.5795 759.68 0.1279 3.62188 21.49

25.2870 543.04 0.1535 3.52213 15.36

25.7950 230.10 0.1535 3.45390 6.51

26.1041 272.44 0.0768 3.41371 7.71

26.7841 1050.92 0.1791 3.32856 29.73

27.3055 733.34 0.2047 3.26618 20.75

27.9204 368.68 0.2047 3.19563 10.43

28.2701 424.91 0.2047 3.15689 12.02

28.6771 355.41 0.1791 3.11300 10.05

29.3211 337.18 0.1535 3.04607 9.54

30.0823 590.94 0.1023 2.97071 16.72

30.8254 302.08 0.1279 2.90077 8.55

31.4243 255.93 0.1023 2.84684 7.24

33.1065 64.16 0.2047 2.70593 1.81

33.5449 42.56 0.1535 2.67156 1.20

34.0559 152.09 0.1279 2.63264 4.30

34.7678 307.22 0.1023 2.58035 8.69

Example 5: Process for the synthesis of crystalline hydrate Form D of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine

[00246] A reaction vessel was charged with 10 g of the crystalline 2-propanol solvate Form

A of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine and 200 mL water. The slurry was stirred for 2-4 hours. The solid was isolated via filtration and dried on the filter for 1-2 hours to afford the crystalline hydrate Form D of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4-yl)- 6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine . The resulting solid exhibited the powder X-ray diffraction pattern displayed in Figures 17-18, and Table 5, the DSC and TGA displayed in Figures 19-20, the infrared spectrum displayed in Figure 21 and the Raman spectra displayed in Figures 22-23.

Table 5. Peak listing for the X-ray powder diffractogram of crystalline hydrate Form D of 5- { [(2 S, 5R)-2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine

Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [A] Rel. Int. [%]

5.5630 690.13 0.0768 15.88671 4.00

8.3060 5435.10 0.0768 10.64530 31.51

10.0280 879.24 0.0768 8.82087 5.10

10.2012 893.49 0.0768 8.67151 5.18

10.5593 1995.84 0.1023 8.37818 11.57

11.0555 883.63 0.0768 8.00324 5.12

11.5183 320.77 0.1023 7.68270 1.86

11.8781 129.95 0.1279 7.45081 0.75

12.8085 69.41 0.1023 6.91160 0.40

13.6019 2957.43 0.1279 6.51016 17.14

14.0165 4349.92 0.1279 6.31852 25.22

14.3661 369.35 0.0768 6.16556 2.14

15.4007 633.14 0.1279 5.75361 3.67

15.9161 966.01 0.1023 5.56843 5.60

16.7238 2308.41 0.1279 5.30125 13.38

17.1424 1291.23 0.1279 5.17275 7.49

17.9407 17250.59 0.1791 4.94434 100.00

18.1017 7667.64 0.0512 4.90072 44.45

18.5141 1832.80 0.1279 4.79249 10.62

18.8004 1799.56 0.1279 4.72013 10.43

19.7326 1228.73 0.1535 4.49920 7.12

20.1720 765.07 0.1023 4.40217 4.44

20.4586 4099.20 0.1535 4.34116 23.76

21.0178 391.95 0.1023 4.22690 2.27

21.4381 355.28 0.1023 4.14498 2.06

21.6873 505.08 0.1535 4.09791 2.93

22.2036 553.03 0.1791 4.00377 3.21

22.7313 1258.93 0.1535 3.91200 7.30

23.1886 293.46 0.0768 3.83589 1.70

23.5022 802.91 0.1535 3.78540 4.65 23.9072 1323.54 0.1791 3.72219 7.67

24.8266 1308.18 0.1535 3.58638 7.58

25.3477 294.63 0.1279 3.51382 1.71

26.4001 712.70 0.1791 3.37610 4.13

27.2824 473.91 0.1791 3.26889 2.75

28.2575 1083.07 0.2047 3.15826 6.28

28.4360 661.36 0.1023 3.13884 3.83

29.0530 408.09 0.2303 3.07357 2.37

29.6230 525.69 0.2303 3.01572 3.05

30.3425 340.97 0.1535 2.94582 1.98

31.0351 150.13 0.1791 2.88164 0.87

32.0059 168.87 0.2047 2.79642 0.98

32.5007 33.40 0.2047 2.75497 0.19

33.2227 429.46 0.2047 2.69673 2.49

33.5621 380.49 0.1791 2.67024 2.21

34.7368 234.98 0.1535 2.58258 1.36

Example 6: Process for the synthesis of crystalline hydrate Form L of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine

[00247] A reaction vessel was charged with 2 g of amorphous solid 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine and 100 mL of water. The slurry was stirred and heated to 60 °C for 2 hours. The solid was isolated via hot filtration, yielding 1.12 g of material. The resulting solid exhibited the powder X-ray diffraction pattern displayed in Figures 24-25, and Table 6, the DSC and TGA displayed in Figures 26-27, the infrared spectrum displayed in Figure 28 and the Raman spectra displayed in Figure 29-30.

Table 6. Peak listing for the X-ray powder diffractogram of crystalline hydrate Form L of 5- { [(2 S, 5R)-2, 5 -dimethyl -4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin- 1 -yl] carbonyl } -N-(5 -fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine

Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [A] Rel. Int. [%]

3.0992 198.60 0.2558 28.50850 11.88

5.6875 189.52 0.2047 15.53922 11.34

7.3367 875.84 0.0768 12.04940 52.39

7.7184 778.87 0.1023 11.45434 46.59

8.4128 1045.52 0.1023 10.51042 62.54

8.7352 312.43 0.1023 10.12329 18.69 9.4626 248.39 0.1023 9.34658 14.86

9.9438 107.95 0.0768 8.89539 6.46

10.4116 304.46 0.0768 8.49675 18.21

11.1849 956.96 0.1279 7.91093 57.24

11.7679 400.75 0.1023 7.52034 23.97

12.0141 476.70 0.0768 7.36678 28.51

12.3836 67.54 0.1023 7.14778 4.04

13.9488 988.27 0.1023 6.34902 59.11

14.2513 725.29 0.1023 6.21496 43.38

14.7487 496.69 0.0768 6.00643 29.71

14.9540 629.52 0.0768 5.92443 37.65

15.5148 364.82 0.0768 5.71154 21.82

15.6636 573.78 0.0768 5.65761 34.32

15.9816 749.15 0.1023 5.54573 44.81

16.5007 800.16 0.1023 5.37242 47.86

16.8936 504.28 0.0768 5.24835 30.16

17.0260 665.98 0.1023 5.20784 39.83

17.3416 1671.90 0.1023 5.11377 100.00

17.5649 802.14 0.1023 5.04927 47.98

17.8362 906.95 0.1279 4.97307 54.25

18.2227 372.06 0.0768 4.86846 22.25

18.4737 375.78 0.1279 4.80288 22.48

19.0459 485.98 0.1535 4.65984 29.07

20.2820 493.50 0.1535 4.37855 29.52

21.1457 568.45 0.1279 4.20162 34.00

21.5774 457.90 0.1279 4.11853 27.39

22.4297 499.99 0.1535 3.96393 29.91

23.1183 241.96 0.1279 3.84739 14.47

23.4118 989.13 0.1535 3.79982 59.16

24.4459 153.39 0.1279 3.64138 9.17

24.9424 166.56 0.1791 3.57000 9.96

25.2820 92.01 0.1279 3.52281 5.50

25.7449 114.48 0.1023 3.46051 6.85

26.4916 169.99 0.1535 3.36464 10.17

26.7999 120.42 0.1535 3.32663 7.20

27.3858 101.08 0.0768 3.25677 6.05

28.2746 203.68 0.1279 3.15639 12.18

28.5404 104.74 0.1023 3.12760 6.27

29.2441 136.15 0.1023 3.05392 8.14

30.2344 48.05 0.2047 2.95611 2.87

30.6752 54.83 0.1791 2.91463 3.28 31.1253 108.48 0.1279 2.87350 6.49

31.5101 114.77 0.2047 2.83928 6.86

32.1968 98.33 0.2558 2.78027 5.88

32.7310 99.94 0.1023 2.73611 5.98

33.6855 47.23 0.1023 2.66074 2.83

34.2749 57.08 0.0768 2.61632 3.41

Example 7: Process for the synthesis of crystalline Form G of 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4- yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-a mine

[00248] A reaction vessel was charged with 1 g of amorphous solid 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine and 20 mL of EtOH. The solution was stirred and heated to 60 °C for about 1 hour. The solution was held at 60 °C while nitrogen gas was passed over the solution, evaporating the solvent and concentrating the reaction mixture until crystallization began. The solution was then allowed to slowly cool overnight to afford crystalline material. The crystalline solid was isolated by filtration and dried at 55 °C. The resulting solid exhibited the powder X-ray diffraction pattern displayed in Figures 31-32, and Table 7, and the DSC and TGA displayed in Figures 33-34.

Table 7. Peak listing for the X-ray powder diffractogram of crystalline Form G of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine

Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [A] Rel. Int. [%]

3.1672 891.23 0.0768 27.89703 12.86

4.3834 6931.96 0.1023 20.15889 100.00

5.4897 330.94 0.2047 16.09860 4.77

6.2044 1288.01 0.0512 14.24578 18.58

6.3899 3790.66 0.1023 13.83258 54.68

8.6938 607.37 0.1023 10.17139 8.76

9.0652 444.30 0.1023 9.75546 6.41

9.7777 119.45 0.0768 9.04615 1.72

10.2389 2157.07 0.1023 8.63965 31.12

11.2467 983.77 0.1279 7.86760 14.19

11.8707 278.59 0.1279 7.45540 4.02

12.3338 692.41 0.1023 7.17652 9.99

12.8049 5399.63 0.1023 6.91351 77.89 12.9862 3094.86 0.0768 6.81741 44.65

13.3662 354.08 0.1535 6.62445 5.11

14.0133 2211.62 0.1023 6.31995 31.90

14.5229 1052.58 0.1279 6.09933 15.18

15.0822 1158.80 0.1791 5.87436 16.72

15.4766 1477.85 0.1535 5.72554 21.32

15.7997 1205.59 0.1023 5.60917 17.39

16.0464 1349.02 0.1023 5.52348 19.46

16.4905 188.08 0.1279 5.37572 2.71

17.4901 3355.74 0.1535 5.07068 48.41

17.7745 2248.51 0.1023 4.99018 32.44

18.0179 1355.40 0.1279 4.92333 19.55

18.6063 2679.28 0.1279 4.76894 38.65

18.8665 1133.73 0.0512 4.70376 16.36

19.0860 2899.34 0.1535 4.65015 41.83

19.6262 404.17 0.1279 4.52335 5.83

20.0698 166.76 0.1023 4.42436 2.41

20.5929 1626.38 0.2047 4.31314 23.46

20.9838 697.62 0.1279 4.23367 10.06

21.4061 1154.31 0.1791 4.15110 16.65

22.2105 447.69 0.1023 4.00254 6.46

22.3974 577.13 0.0512 3.96956 8.33

22.6356 1403.27 0.1023 3.92833 20.24

22.9179 1502.49 0.1279 3.88057 21.67

23.2023 963.24 0.1279 3.83365 13.90

23.8591 843.13 0.2047 3.72959 12.16

24.2484 611.50 0.1279 3.67058 8.82

24.6862 603.74 0.1535 3.60647 8.71

25.1765 973.86 0.1791 3.53733 14.05

25.5023 143.35 0.0768 3.49288 2.07

25.8431 470.21 0.1791 3.44758 6.78

26.1733 1089.43 0.1535 3.40483 15.72

26.9377 271.79 0.1023 3.30992 3.92

27.5800 57.80 0.1535 3.23428 0.83

27.9121 231.35 0.0768 3.19656 3.34

28.3654 786.82 0.1535 3.14649 11.35

28.8139 643.08 0.1535 3.09853 9.28

29.1637 527.47 0.1535 3.06216 7.61

29.4832 211.62 0.1023 3.02969 3.05

29.9991 354.99 0.1535 2.97876 5.12

30.7636 157.51 0.1535 2.90645 2.27 31.9908 376.81 0.1279 2.79771 5.44

32.8014 249.45 0.1279 2.73040 3.60

33.6788 195.64 0.1279 2.66125 2.82

34.2423 74.36 0.1535 2.61873 1.07

Example 8: Process for the synthesis of crystalline Form H of 5-{[(2S,5R)-2,5-dimethyl-4-

(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4- yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-a mine

[00249] A reaction vessel was charged with 1 g of amorphous solid 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine and 14 mL of

CH ₃ CN. The suspension was stirred and heated to 80 °C for 5 hours. The solid was isolated via hot filtration and dried at 55 °C. The resulting solid exhibited the powder X-ray diffraction pattern displayed in Figures 35-36, and Table 8, and the DSC and TGA displayed in Figures 37-38.

Table 8. Peak listing for the X-ray powder diffractogram of crystalline Form H of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine

Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [A] Rel. Int. [%]

3.0930 922.45 0.0768 28.56528 16.01

3.4623 858.41 0.0768 25.51979 14.90

3.7214 1002.49 0.0768 23.74331 17.40

4.3050 5761.00 0.0768 20.52571 100.00

4.8848 1042.74 0.1279 18.09080 18.10

5.2922 1027.76 0.0768 16.69897 17.84

5.7296 574.24 0.1023 15.42521 9.97

6.2279 612.97 0.1279 14.19205 10.64

6.9617 246.22 0.0512 12.69760 4.27

7.5776 83.70 0.3070 11.66691 1.45

10.0012 598.63 0.0768 8.84447 10.39

10.4954 192.91 0.1279 8.42909 3.35

10.6820 215.23 0.0768 8.28224 3.74

11.1198 766.71 0.0768 7.95716 13.31

11.6640 336.86 0.1023 7.58707 5.85

12.2039 196.89 0.0768 7.25259 3.42

12.5522 951.49 0.1023 7.05214 16.52

12.8646 1197.30 0.1279 6.88159 20.78

13.1130 2313.45 0.0768 6.75176 40.16 13.2878 1134.51 0.0768 6.66336 19.69

14.1311 1182.73 0.1023 6.26753 20.53

14.4939 257.96 0.0768 6.11148 4.48

14.7071 278.75 0.1023 6.02336 4.84

15.3319 587.84 0.1023 5.77925 10.20

15.9237 506.90 0.1535 5.56579 8.80

16.7038 853.13 0.2303 5.30756 14.81

17.5492 645.84 0.0768 5.05375 11.21

17.7443 1462.08 0.1279 4.99862 25.38

18.0546 1168.83 0.2047 4.91340 20.29

18.8622 2263.23 0.1279 4.70480 39.29

19.6876 180.88 0.1279 4.50938 3.14

20.1549 279.92 0.1279 4.40589 4.86

20.5942 234.25 0.1023 4.31288 4.07

21.5782 216.48 0.3070 4.11838 3.76

22.3720 529.04 0.1279 3.97401 9.18

22.6009 318.28 0.0768 3.93428 5.52

22.9708 146.62 0.1279 3.87175 2.55

23.2981 128.68 0.1023 3.81809 2.23

23.7100 347.34 0.1791 3.75269 6.03

23.9304 351.85 0.0768 3.71862 6.11

24.6578 70.05 0.1535 3.61055 1.22

25.2428 359.68 0.1023 3.52819 6.24

26.8677 185.62 0.1023 3.31839 3.22

28.1046 131.15 0.2047 3.17510 2.28

28.4386 112.67 0.1279 3.13857 1.96

29.9739 88.40 0.1535 2.98121 1.53

30.4594 49.98 0.1279 2.93478 0.87

31.8405 22.73 0.1791 2.81057 0.39

32.6315 56.01 0.3070 2.74423 0.97

Example 9: Process for the synthesis of crystalline Form I of 5-{[(2S,5R)-2,5-dimethyl-4-

(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4- yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-a mine

[00250] A reaction vessel was charged with 1 g of amorphous solid 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine and 50 mL of

Et ₂ 0. The suspension was stirred and heated to 30 °C for 5 hours. The solid was isolated via hot filtration and dried at 55 °C. [00251] An alternative preparation of the crystalline solid of Form I was achieved by charging a reaction vessel with 1 g of amorphous solid 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H- pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-meth ylpyrimidin-4-yl)-6,6-dimethyl- l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine and 50 mL of methyl ethyl ketone. The solution was stirred and heated to 60 °C for about 1 hour. The solution was held at 60 °C while nitrogen gas was passed over the solution, evaporating the solvent and concentrating the reaction mixture until crystallization began. The solution was then allowed to slowly cool overnight to afford crystalline material. The solid was isolated by filtration and dried at 55 °C. The resulting solids from both preparations exhibited the powder X-ray diffraction pattern displayed in Figures 39-40, and Table 9, and the DSC and TGA displayed in Figures 41-42.

Table 9. Peak listing for the X-ray powder diffractogram of crystalline Form I of 5-{[(2S,5R)-2,5- dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]ca rbonyl}-N-(5-fluoro-2- methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-amine

Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [A] Rel. Int. [%]

4.0731 43.01 0.4093 21.69391 0.46

4.3427 115.06 0.0768 20.34782 1.23

5.5083 656.95 0.0768 16.04437 7.04

5.7151 275.84 0.0768 15.46416 2.96

6.7017 12.46 0.3070 13.18967 0.13

8.7564 1484.80 0.1023 10.09883 15.92

9.5087 388.35 0.0512 9.30142 4.16

10.0391 3286.18 0.1279 8.81113 35.23

10.4596 7112.00 0.1279 8.45783 76.24

11.0863 795.84 0.0768 7.98112 8.53

11.4510 3567.88 0.1279 7.72771 38.25

12.4105 4192.64 0.1279 7.13235 44.94

12.8969 249.53 0.0768 6.86441 2.67

13.4212 4726.90 0.1279 6.59742 50.67

14.0940 63.40 0.1535 6.28394 0.68

14.7950 312.95 0.1279 5.98775 3.35

15.6550 9328.88 0.1279 5.66069 100.00

16.0269 1638.18 0.0768 5.53019 17.56

16.2734 2146.72 0.0768 5.44696 23.01

16.4440 1924.64 0.1279 5.39085 20.63

17.2048 861.47 0.1279 5.15412 9.23

17.5888 1822.40 0.1279 5.04246 19.54

18.7002 514.07 0.1535 4.74519 5.51

19.3264 1490.04 0.2047 4.59284 15.97

19.8539 1061.34 0.1279 4.47199 11.38

20.1935 464.22 0.1535 4.39754 4.98 20.7352 609.58 0.1535 4.28388 6.53

21.2813 1028.46 0.2303 4.17516 11.02

21.9984 2223.41 0.1791 4.04065 23.83

23.1627 715.41 0.1535 3.84011 7.67

23.5262 1103.15 0.2047 3.78160 11.83

23.9307 211.75 0.0768 3.71858 2.27

24.7383 571.53 0.1279 3.59899 6.13

25.0316 1089.44 0.1279 3.55749 11.68

25.6969 540.10 0.1791 3.46687 5.79

26.0210 751.12 0.1279 3.42441 8.05

27.1503 20.59 0.1535 3.28449 0.22

27.7785 64.82 0.1535 3.21162 0.69

28.6746 214.56 0.1535 3.11327 2.30

Pharmaceutical Dosage Forms

[00252] Example 10: A tablet is prepared by mixing 48 % by weight of amorphous 5-

{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl) piperazin-l-yl]carbonyl}-N-(5-fluoro- 2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrro lo[3,4-c]pyrazol-3-amine, 45 % by weight of microcrystalline cellulose, 5 % by weight of low- substituted hydroxypropyl cellulose, and 2 % by weight of magnesium stearate. Tablets are prepared by direct compression. The total weight of the compressed tablets is maintained at 250-500 mg.

[00253] Example 11: A tablet is prepared by mixing 48 % by weight of crystalline hydrate

Form B of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine, 40 % by weight of microcrystalline cellulose, 5 % by weight of low- substituted

hydroxypropyl cellulose, 5 % by weight of croscarmellose sodium, and 2 % by weight of magnesium stearate. Tablets are prepared by direct compression. The total weight of the compressed tablets is maintained at 250-500 mg.

[00254] Example 12: A tablet is prepared by mixing 48 % by weight of crystalline hydrate

Form D of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine, 45 % by weight of microcrystalline cellulose, 5 % by weight of low- substituted

hydroxypropyl cellulose, and 2 % by weight of magnesium stearate. Tablets are prepared by direct compression. The total weight of the compressed tablets is maintained at 250-500 mg.

[00255] Example 13: A tablet is prepared by mixing 48 % by weight of crystalline hydrate

Form L of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}- N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tet rahydropyrrolo[3,4-c]pyrazol-3- amine, 40 % by weight of microcrystalline cellulose, 5 % by weight of low- substituted

hydroxypropyl cellulose, 5 % by weight of croscarmellose sodium, and 2 % by weight of magnesium stearate. Tablets are prepared by direct compression. The total weight of the compressed tablets is maintained at 250-500 mg.

[00256] Example 14: A tablet is prepared by mixing 48 % by weight of crystalline Form G of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine, 40 % by weight of microcrystalline cellulose, 5 % by weight of low-substituted hydroxypropyl cellulose, 5 % by weight of croscarmellose sodium, and 2 % by weight of magnesium stearate. Tablets are prepared by direct compression. The total weight of the compressed tablets is maintained at 250-500 mg. [00257] Example 15: A tablet is prepared by mixing 48 % by weight of crystalline Form H of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine, 40 % by weight of microcrystalline cellulose, 5 % by weight of low-substituted hydroxypropyl cellulose, 5 % by weight of croscarmellose sodium, and 2 % by weight of magnesium stearate. Tablets are prepared by direct compression. The total weight of the compressed tablets is maintained at 250-500 mg.

[00258] Example 16: A tablet is prepared by mixing 48 % by weight of crystalline Form I of

5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethy l)piperazin-l-yl]carbonyl}-N-(5- fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-l,4,5,6-tetrahyd ropyrrolo[3,4-c]pyrazol-3-amine, 40 % by weight of microcrystalline cellulose, 5 % by weight of low-substituted hydroxypropyl cellulose, 5 % by weight of croscarmellose sodium, and 2 % by weight of magnesium stearate. Tablets are prepared by direct compression. The total weight of the compressed tablets is maintained at 250-500 mg.

Treatment of Uveitis

Example 17: Evaluate the efficacy and safety of amorphous 5-{[(2S,5R)-2,5-dimethyl-4- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-( 5-fluoro-2-methylpyrimidin-4- yl)-6,6-dimethyl-l,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-a mine in subjects with Uveitis

[00259] Study design: Allocation: randomized

Endpoint Classification: Safety/Efficacy Study

Intervention Model: Parallel Assignment

Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment

[00260] Primary Outcome Measures:

• Control of intraocular inflammation [ Time Frame: at 6-month visit ]

[ Designated as safety issue: No ]

Absence of intraocular inflammation (e.g. less than trace AC cells; no vitreous haze; inactive chorioretinal lesions).

• Evaluation of Adverse Events [ Time Frame: Baseline to Final Visit (Final Visit could occur at any point up to 52 weeks) ] [ Designated as safety issue: Yes ]

• Significant laboratory value changes [ Time Frame: Baseline to Final Visit (Final Visit could occur at any point up to 52 weeks) ] [ Designated as safety issue: Yes ] Significant vital sign changes [ Time Frame: Baseline to Final Visit (Final Visit could occur at any point up to 52 weeks) ] [ Designated as safety issue: Yes ]

[00261] Secondary Outcome Measures:

Control of intraocular inflammation [ Time Frame: 12-month clinical visit ]

[ Designated as safety issue: No ]

Proportion of subjects at each study time point with no new active, inflammatory chorioretinal or inflammatory retinal vascular lesion in both eyes relative to Baseline for subjects who had inactive uveitis when they entered the study. [ Time Frame: Final Visit (Final Visit could occur at any point up to 52 weeks) ] [ Designated as safety issue: No ]

Proportion of subjects at each study time point with no new active, inflammatory chorioretinal or inflammatory retinal vascular lesion in both eyes relative to Week 8 for subjects who had active uveitis when they entered the study. [ Time Frame: Final Visit (Final Visit could occur at any point up to 52 weeks) ] [ Designated as safety issue: No ]

Proportion of subjects at each study time point with a Grade <= 0.5+ in AC cells in both eyes on Slit Lamp Exam according to SUN criteria. [ Time Frame: Final Visit (Final Visit could occur at any point up to 52 weeks) ] [ Designated as safety issue: No ]

Proportion of subjects at each study time point with a Grade <= 0.5+ in vitreous haze in both eyes on indirect ophthalmoscopy according to NEI/SUN criteria. [ Time Frame: Final Visit (Final Visit could occur at any point up to 52 weeks) ] [ Designated as safety issue: No ]

Proportion of subjects at each study time point without a worsening of BCVA by >= 15 letters on the ETDRS in both eyes relative to Baseline for subjects who had inactive uveitis when they entered the study. [ Time Frame: Final Visit (Final Visit could occur at any point up to 52 weeks) ] [ Designated as safety issue: No ]

Proportion of subjects at each study time point without a worsening of BCVA by >= 15 letters on the ETDRS in both eyes relative to Week 8 for subjects who had active uveitis when they entered the study. [ Time Frame: Final Visit (Final Visit could occur at any point up to 52 weeks) ]

[ Designated as safety issue: No ]

Percent change in central retinal thickness (1 mm subfield) in each eye at each study time point relative to Baseline for subjects who had inactive uveitis when they entered the study.

[ Time Frame: Baseline to Final Visit (Final Visit could occur at any point up to 52 weeks) ]

[ Designated as safety issue: No ]

Percent change in central retinal thickness (1 mm subfield) in each eye at each study time point relative to Week 8 for subjects who had active uveitis when they entered the study. [ Time Frame: Week 8 to Final Visit (Final Visit could occur at any point up to 52 weeks) ]

[ Designated as safety issue: No ]

Change in NEI Visual Functioning Questionnaire (VFQ-25) score at each study time point relative to Baseline for subjects who had inactive uveitis when they entered the study.

[ Time Frame: Baseline to Final Visit (Final Visit could occur at any point up to 52 weeks) ]

[ Designated as safety issue: No ]

Change in NEI Visual Functioning Questionnaire (VFQ-25) score at each study time point relative to week 8 for subjects who had active uveitis when they entered the study.

[ Time Frame: Week 8 to Final Visit (Final Visit could occur at any point up to 52 weeks) ]

[ Designated as safety issue: No ]

Proportion of subjects at each study time point achieving a >= 50 % reduction in

immunosuppression load relative to Baseline for subjects who had inactive uveitis when they entered the study. [ Time Frame: Final Visit (Final Visit could occur at any point up to 52 weeks) ] [ Designated as safety issue: No ]

Proportion of subjects at each study time point achieving a >= 50 % reduction in

immunosuppression load relative to Week 8 for subjects who had active uveitis when they entered the study. [ Time Frame: Final Visit (Final Visit could occur at any point up to 52 weeks) ]

[ Designated as safety issue: No ]

[00262] Other Outcome Measures:

Elevation of IOP [ Time Frame: At 3-month, 6-month, and 12-month visit ]

[ Designated as safety issue: Yes ]

Ocular hypertension and IOP>30 and 10 mm Hg increase or greater in IOP will be assessed.

Progression of cataract or need for cataract surgery [ Time Frame: At 3-month, 6-month, and 12- month visit ] [ Designated as safety issue: Yes ]

predetermined dosing intervals as specified in the protocol

Experimental: amorphous 5-{[(2S,5R)-2,5-dimefhyl-4- High dose of amorphous 5-{[(2S,5R)-2,5-dimefhyl-4- (tetrahydro -2H-pyran-4-ylmethyl)piperazin- 1 -y 1] carbonyl } -N- (tetrahydro-2H-pyran-4-ylmethyl)piperazin-l- (5 -fluoro -2 -methy lpy rimidin-4 -y 1) -6 , 6 -dimethyl- 1,4,5,6- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine High-dose Group. dimethyl- 1 ,4,5,6-tetrahydropyrrolo [3 ,4-c]pyrazol-3 - Amoφhous 5-{ [(2S,5R)-2,5-dimefhyl-4-(tetrahydro-2H- amine administered at predetermined intervals pyran-4-ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2- methy lpy rimidin-4 -y 1) -6 , 6 -dimethyl- 1,4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine will be given at the

predetermined dosing intervals as specified in the protocol

Placebo Comparator: Matching Placebo Group Other: Placebo

Placebo matching experimental dose will be given at the Matching placebo to experimental dose administered at predetermined dosing intervals as specified in the protocol predetermined intervals

Detailed Description:

[00263] Background: Intermediate and posterior uveitis are known to induce severe intraocular inflammation that may lead to permanent visual loss. It is estimated that these forms of uveitis comprise the fifth or sixth leading cause of blindness and tend to affect working class age patients, thus causing loss of work hours and diminished productivity and quality of life. Because disease in the posterior segment of the eye is not adequately treated by corticosteroid drops often systemic drug therapy is used including oral corticosteroids or prednisone. Prednisone can have a myriad of side effects. In approximately one-quarter to one-third of cases treated in tertiary care centers, additional medications such as immunosuppressive drugs are required to control the disease and/or to allow for appropriate tapering of oral prednisone to subsequent levels that have a low side effect profile when delivered over a long period of time. Typically, chronic prednisone therapy in doses of 7.5 mg daily or less are thought to have a low enough side effect profile to be amenable to long-term therapy. However frequently additional immunosuppressive drugs are required to get the dosing to this level. There are occasions when patients are intolerant of any dose of oral corticosteroids or are intolerant of the higher doses of oral corticosteroids (30 - 60 mg daily) and therefore this treatment modality is avoided due to prednisone's attendant side effects.

Although periocular and intravitreal corticosteroids injections may be performed, with these modalities the standard of care is to wait until the disease reactivates before instituting such therapy and therefore a chronic suppressive dose is not obtained. The fluocinolone acetonide implant (Retisert®, Bausch and Lomb, Tampa, FL) is FDA-approved for the treatment of intermediate and posterior uveitis and it is equally effective in controlling uveitis as high-dose oral corticosteroids

- i l l - but avoids the systemic side effects associated with the use of high doses of oral corticosteroids.

However, this form of local therapy has high rates of ocular side effects, including ocular hypertension causing glaucoma and/or requiring glaucoma surgery and cataracts. Furthermore, every two and half to three years the implant is exhausted of corticosteroid and therefore repeat surgical insertion of another implant may be required.

[00264] Eligibility

Ages Eligible for Study: 18 Years and older

Gender Eligible for Study: Both

Accepts Healthy Volunteers: No

[00265] Inclusion Criteria:

• Active sight-threatening intermediate or posterior uveitis.

• Patients must be age 18 years or older and sign an informed consent.

• The ocular media must be clear enough to obtain OCT and fundus photographs.

• No elective intraocular surgery should be planned for the first 3 months after enrollment.

[00266] Exclusion Criteria:

• Infectious uveitis

• History of scleritis

• Active or suspected viral infection of the cornea or conjunctiva

• History of mycobacterial or fungal disease

• HIV positivity

• Age <18 years old

• Uncontrolled IOP

• Advanced glaucoma

• Aphakia with rupture of the posterior lens capsule

• ACIOL with rupture of the posterior lens capsule

• Media opacity that would preclude evaluation of the posterior pole via fundus photography or OCT assessment

• Planned elective ocular surgery within 3 months of enrollment Additional Experiments

Example 18: HPLC Isolation of 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l,4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine

Aims and Objectives

[00267] To assess the propensity of 5-{ [(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine to form amorphous or crystalline phases following isolation from a CH ₃ CN/water eluent system, post transit/purification via a C18 reverse phase column.

Summary

[00268] Isolation of 5-{ [(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)pipe razin- l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimet hyl- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine using acetonitrile (CH ₃ CN) and water systems provided varied results.

[00269] Three trials were completed:

18A CH ₃ CN

18B CH ₃ CN/water (9: l)

18C CH ₃ CN/water (l :9)

[00270] The trial using CH ₃ CN provided an amorphous solid. The two wet systems provided either partially crystalline or highly crystalline solids in the form of Pattern L. The crystalline phases did not dry back to amorphous solids.

Characterization of Input Solid

[00271] 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine was analyzed as received with the appearance of a beige to off-white glassy solid. Chemical purity by HPLC (generic low-pH method) was 92.98%. 1H MR spectroscopy revealed a spectrum that conformed to structure (D ₆ DMSO). XRPD examination (Figure 43) revealed that the solid was completely amorphous for both samples tested.

General Procedure for Isolation Following Elution via a C18 Reverse Phase Column

[00272] 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)p iperazin-l- yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethy l- 1,4,5, 6-tetrahydropyrrolo[3,4- c]pyrazol-3-amine (150 mg) was dissolved in eluent at 45-50 mL and eluted via a C18 reverse phase column at 2 mL/minute. This was followed by flushing the column and testing for product content using 50-100 mL of eluent. The eluent was reduced in vacuo using a rotary evaporator at 35 °C to produce solids for analysis. The resulting samples were then dried overnight at 18-35 °C in vacuo ahead of analysis. In some instances, analysis of the damp solids was collected.

[00273] Column details: C18 Phenomenex 5 micron, Luna; 100 A; 150 X 4.6 mm

Example 18A: 100% CH ₃ CN

[00274] The column was loaded with 5-{ [(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine in 50 mL of CH ₃ CN. Note that precipitation of a voluminous solid takes place over 10 minutes in 10 mL CH3CN used to initially mobilize solids. At 50 mL volume with warming at <40 °C, dissolution takes place. Clarification via a 0.45 micron frit was employed prior to chromatography.

[00275] Elution was completed using 40 mL CH ₃ CN.

[00276] Evaporation at 35 ° C was complete within 2 hours and dried at 18 °C overnight (18 h) in vacuo.

[00277] The resulting solid was a yellow glass in appearance.

[00278] Result: XRPD of the solid post reduction in vacuo was amorphous (Figure 44).

Example 18B: 9:1 CH ₃ CN:water

[00279] The column loaded with 5-{ [(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine in 50 mL CH ₃ CN/water (9: 1). Solids dissolved at 50 mL volume with warming at <40 °C, dissolution readily takes place. Clarification via a 0.45 micron frit was employed prior to chromatography.

[00280] Elution was complete using 50 mL CH ₃ CN/water (9: 1).

[00281] Evaporation at 35 °C was complete within 2.9 hours and dried at 18 °C overnight

(18 h) in vacuo. Solids remain damp.

[00282] The resulting mass was a yellow glass in appearance with white granular solids present.

[00283] Result: XRPD of the solid post drying in vacuo was predominantly amorphous, or equally relevant, partially crystalline, XRPD pattern (Figure 45).

[00284] The solids post drying in vacuo at 35 °C to remove further water demonstrated a predominantly amorphous, or equally relevant, partially crystalline, XRPD pattern (Figure 46). Example 18C: 1:9 CH ₃ CN:water

[00285] The column was loaded with 5-{ [(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine in 45 mL CH ₃ CN/water (1 :9) and 5 mL CH3CN used to mobilize the solid (50 mL total). Solids dissolved at 50 mL volume with warming at <40 °C, dissolution takes place following mild agitation. Clarification via a 0.45 micron frit was employed prior to chromatography.

[00286] Elution was complete using 50 mL CH ₃ CN/water (1 :9).

[00287] Evaporation of half of the batch at 35 °C was complete within 3 hours to leave an aqueous emulsion/solid state that was held overnight due to time constraints. The remainder was reduced in vacuo the next day and 6 h were required to remove water without product loss due to bumping at <35 °C.

[00288] The resulting mass was a white powder in appearance in the damp state.

[00289] Result: XRPD of the solid post reduction in vacuo was highly crystalline (Figure

47).

[00290] The solids post drying in vacuo at 35 °C to remove further water demonstrated a highly crystalline and equivalent profile (Figure 48).

Conclusions

[00291] The crystalline phase represented within Example 18B and 18C was identified as

Pattern L. This phase requires drying at temperatures in excess of 70 °C to remove water and provide an amorphous phase.

[00292] Isolation of 5-{ [(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4- ylmethyl)piperazin-l-yl]carbonyl}-N-(5-fluoro-2-methylpyrimi din-4-yl)-6,6-dimethyl-l, 4,5,6- tetrahydropyrrolo[3,4-c]pyrazol-3-amine from acetonitrile/water provides crystalline or partially crystalline solids with results varying dependent upon the starting eluent composition being removed and the conditions employed within the laboratory. Standard drying conditions of <40 °C in vacuo do not return an amorphous solid.

[00293] Use of acetonitrile alone provides amorphous solids, but this does require speed or a solid phase that is likely to be a solvate will form.